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Abstract 
Substance use within the LGBTIQ community has been long established. However 
chemsex, the use of recreational substances within the context of sexual activity (for 
the purpose of enhancement), is a new and emerging area of research, particularly in 
Australia. Chemsex is most commonly associated with men who have sex with men 
(MSM) and often involves stimulants, such as crystal methamphetamine. The 
current study was developed in partnership with the Queensland AIDS Council to 
inform future health promotion. Participants were 663 MSM, the majority of whom 
resided in South East Queensland. Questionnaires were completed online or on 
paper. The questionnaire asked about demographic details, substances used in the 
last 12 months, sexual health details and engagement in a variety of sexual 
behaviours, including chemsex. Those who reported engagement in chemsex were 
asked further questions about these behaviours. Descriptive results provided rates of 
substance use within particular sub-groups. In addition, it was found that crystal 
methamphetamine was associated with increased rates of condomless anal 
intercourse (CAI); increased sexual session length was found to increase the 
likelihood of engagement in CAI; chemsex, use of PrEP and having an undetectable 
viral load (UVL) were also shown to be significant predictors of CAI. Finally, 
chemsex and PrEP were shown to be significantly associated with increased 
reporting of sexually transmitted infections. These results provide useful insight for 
future HIV prevention, health promotion and clinical intervention planning. 
Implications for chemsex participants and the wider MSM community are discussed 
and recommendations for future research are made.  
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Glossary of Terms 
Antiretrovirals (ARV): An umbrella term for all antiretroviral medications, 
whether they are used as part of an HIV treatment regime (ART) or as PrEP or PEP 
Antiretroviral therapy (ART): Usually a three drug treatment regime for people 
living with HIV 
BBV: Blood Borne Virus 
CAI: Condomless Anal Intercourse  
Cisgender: Someone who identifies with the gender they were assigned at birth 
Harm minimisation: An overarching term referring to harm reduction, supply 
reduction and demand reduction 
Hep A/B/C: Hepatitis strains A, B or C. Strain A and B are vaccine preventable 
Strains B and C are difficult to treat and considered chronic once acquired. Strain A 
is straightforward to treat baring complications such as immune deficiency  
HIV: Human Immunodeficiency Virus  
Intersex: Someone who was born with reproductive or sexual organs that do not fit 
the standard definitions of ‘male’ or ‘female’  
LGBTIQ: Lesbian, Gay, Bisexual, Trans, Intersex, Queer/Questioning 
Men who have sex with men (MSM): This term is used because it names 
behaviour rather than identity, for example some MSM identify as heterosexual. The 
term does include bisexual, gay and trans men who have sex with other men 
PLWH: Person/ People living with HIV 
Post Exposure Prophylaxis (PEP): a four week course of medication commenced 
within 72 hours of suspected or confirmed exposure to HIV. It significantly reduces 
the likelihood of acquiring HIV but is not 100% effective 
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Pre-exposure prophylaxis (PrEP): a daily medication that prevents a person who 
has been exposed to HIV from acquiring the virus by blocking the enzyme that 
allows HIV to reproduce in the human body 
Queer: An umbrella terms for anyone who falls into LGBTIQA+. Is also considered 
an identity in itself for someone whose gender or sexuality differs from the ‘norm’. 
It is only acceptable as a self-identity in the same way as ‘black fella’ for an 
Aboriginal person or ‘crip’ for a person with a disability.    
Questioning: Someone who is unsure about aspects of their sexuality or gender    
Serodiscordant: Two or more people with differing HIV status 
Serosorting: The practice of choosing to have sex with only those people who have 
the same HIV status as oneself. i.e., A person who is HIV negative having sex 
within other people who are also HIV negative to reduce the chances of HIV 
acquisition 
STI: Sexually Transmitted Infection 
Trans*: Someone who does not identify with the gender they were assigned at birth, 
they may identify as transgender, agender, multiple genders or another gender 
identity. The asterisk was originally added in order to be inclusive, however the term 
‘trans’, is, at times, considered to be more inclusive.   
Undetectable Viral Load (UVL): When copies of the HIV virus cannot be detected 
on a standard test, usually <50 copies/mL. This effectively makes transmission to 
others impossible. 
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Introduction 
General Aims and Purpose  
This project was initiated at the request of the Queensland AIDS Council 
(QuAC), as they were concerned about anecdotal reports of chemsex behaviour 
within the Queensland community of MSM (men who have sex with men). The 
survey questions and research direction were developed in partnership with the 
Queensland AIDS Council in order to inform future health promotion. Data was 
collected online and in paper forms primarily by QuAC staff and volunteers over a 
three month period in 2016. A number of feedback and collaboration opportunities 
have been a key part of this research project including presentation of a limited 
selection of the results at the Australian Winter School conference in July 2017.   
What is ‘Chemsex’ and Why is it a Problem? 
Substance use within the gay male population is prevalent, both 
recreationally and within the context of sexual activity. Previous research has 
explored and substantiated numerous reasons for substance use including relief and 
escape from stigma and discrimination (D. McKirnan, D. Ostrow, & B. Hope, 1996; 
Mullens, Young, Hamernik, & Dunne, 2009), enhancing sexual experiences (Hurley 
& Prestage, 2009), relief from stressors related to being members of a minority group 
(Meyer, 2003), community expectations (e.g, peer pressure), peer norms (Hughes & 
Eliason, 2002b), sexual disinhibition (Mattison, Ross, Wolfson, & Franklin, 2001) 
and bar and club culture where LGBTIQ people first felt accepted, among other 
reasons (Hardesty, Cao, Shin, Andrews, & Marsh, 2012).  
‘Chemsex’ is a more recently defined construct, (Bourne, Reid, Hickson, 
Torres-Rueda, & Weatherburn, 2014) and refers to “…sex between men that occurs 
under the influence of illicit substances taken immediately preceding and/or during 
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the sexual session.”(Bourne et al., 2014, p. 8). Authors, such as Schmidt et al. (2016) 
and Lim et al. (2015), cite similar definitions, “….simultaneous use of drugs to 
enhance sexual pleasure.” The substances normally associated with chemsex are 
stimulants such as crystal methamphetamine, gamma-hydroxybutyric(GHB)/gamma-
butyrolactone (GBL) and mephedrone. At times, cocaine and ketamine are also used 
during chemsex, though ketamine is not a stimulant but rather an anaesthetic that has 
hallucinogenic effects, when used recreationally is considered a ‘designer drug’. 
Another key feature of chemsex is long sexual sessions and/or large numbers of 
sexual participants (Bourne et al., 2014). Each of these characteristics are associated 
with both individual and compounded risks.  
There are clear risks associated with the most commonly used chemsex drug: 
crystal methamphetamine. These effects include sleep deprivation, lack of nutrition 
and fluids, dental problems, itching and fever (Knoops, Bakker, Bodegom, & 
Zantkuijl, 2015). These side effects are often found subsequent to use of GHB and 
mephedrone as well. Of particular relevance to men who have sex with men (MSM) 
is peripheral numbness resulting from crystal methamphetamine use (Halkitis, 
Parsons, & Stirratt, 2001). This can lead MSM to combine substances such as 
erectile dysfunction medications, in order to combat this side effect. Combining 
substances in this manner can amplify damaging health effects and risks from 
HIV/STI transmission (Connor, Gullo, White, & Kelly, 2014; Spindler et al., 2007). 
There have also been reports that use of crystal methamphetamine has influenced 
absorption of anti-retroviral medications making them less effective, however this 
was reported to be an effect of some of the older HIV treatments (Colfax & Guzman, 
2006; Halkitis et al., 2001). There are also social and mental health risks associated 
with substance use, such as social isolation from non-drug users, increased anxiety 
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and paranoia, the cycle associated with substance use and mental health conditions 
(Knoops et al., 2015), and impulsivity (Halkitis et al., 2001). These risks are well 
documented and the focus of a wide variety of health promotion and harm reduction 
strategies (Degenhardt & Hall, 2012). However in this population, mental health 
effects may be even more pronounced due to homophobia from the general 
community, internalised homophobia and stigma associated with high prevalence 
rates of HIV within the community (Herek & Garnets, 2007; S. Russell & Fish, 
2016). Higher numbers of the LGBTIQ population live in poverty (DeFilippis, 2016) 
or social isolation (Mao et al., 2009) as secondary effects of homophobia (Leonard, 
Lyons, & Bariola, 2015). These disadvantages compound general negative mental 
health effects of drug use, and can lead to substantive and entrenched mental health 
disorders and other psychosocial challenges (Mao et al., 2009; Rosario, Schrimshaw, 
& Hunter, 2006). 
There are also substantial sexual health risks associated with chemsex 
behaviours. Many of these risks such as transmission of HIV, hepatitis and other 
sexually transmitted infections (STI) are the focus of long standing harm reduction 
strategies. The emergence of chemsex among MSM is of significant concern given 
the overlapping and therefore amplified risks of combining of high risk sexual 
activity and drug use (Bourne et al., 2014). In particular, long sexual sessions, in 
combination with disinhibition, and the use of drugs used specifically for sexual 
enhancement (such as Viagra and Amyl Nitrate) can lead to vessel dilation and micro 
tears within the anus. These abrasions often serve as an entry point for HIV or other 
infections (Buchbinder et al., 2005; Shoptaw & Reback, 2007). As such, men who 
take the receptive role during sexual activity, are at greater risk of acquiring HIV. 
Men who are disinhibited from the effects of substances, may also take greater risks 
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that involve blood or substantial fluid exchange, and the use of Viagra (sildenafil; in 
addition to other chemsex factors) increases the likelihood of priapism (prolonged 
erection), which, if untreated, can cause permanent damage (Burnett & Bivalacqua, 
2007). Other sexual health considerations can include implications for increased 
prevalence of STIs with the uptake of PrEP (Scott & Klausner, 2016) as well as the 
possibility of treatment resistant STIs as antibiotic resistance becomes an ever 
increasing concern (Lahra, Ryder, & Whiley, 2014).    
 Chemsex, has been documented across groups of MSM in many parts of the 
world (The EMIS Network, 2013), including Australia (Race, 2015). These studies 
found some men reporting positive attributes of chemsex including improved 
confidence and decreased self-doubt within a sexual context. Some of the reasons 
behind the need for increased confidence relate to internalised homophobia in 
various forms, in addition to body image concerns and for some, coping with a recent 
HIV diagnosis (Bourne et al., 2014). Another highly endorsed reason for wanting to 
engage in chemsex is the desire for increased libido and associated heightened 
physical sensations. Men have also reported that substance use allows them to have 
greater intimacy and connection with a sexual partner (Bourne et al., 2014). While 
these benefits persist, it is also important to consider, as with any drug use, chemsex 
drug use has a tendency to perpetuate itself with associated harms (Bourne, Reid, 
Hickson, Torres-Rueda, Steinberg, et al., 2015). The addictive nature of the 
substances being used (Amaro, 2016), the somewhat isolated social circles resulting 
from sexualised drug use (Ahmed et al., 2016), and the difficulty of returning to 
sober sexual activities after a period of time engaging in sexualised drug use (Bourne 
et al., 2014) all present potential health and social problems among these MSM. 
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Chemsex: As Informed by Public Health and Psychological Science  
This study is based on a number of constructs in order to best understand 
chemsex in an Australian sample. It explores chemsex and the mechanism by which 
the behaviour developed and is perpetuated. This research explores chemsex in light 
of social cognitive theory (Armitage & Conner, 2000; Rosenstock, Strecher, & 
Becker, 1988), the concept of minority stress (Pascoe & Richman, 2009), bio-
psycho-social theory (H. Friedman & Silver, 2007) and the social determinates of 
health (Australian Institute of Health and Welfare, 2016; Marmot, 2005). These 
theories broadly guide the study design and possible implications, however, they are 
not explicitly tested. They will help to contextualise the behaviours of interest and 
their impact on the health and wellbeing of individuals, as well as the broader public 
health implications. The four theories have significant overlap and serve to 
understand outcomes in different ways.      
Bio-psycho-social theory, as the name suggests, considers the bi-directional 
impacts of each influence in order to understand behaviour (Engel, 1977). Social 
cognitive theory (Bandura, 1998), focuses in on learning and expectations, based on 
that learning. However it too places a strong emphasis on behaviour, as the outcome 
variable. The additional two theories, the social determinants of health and minority 
stress theory (Dentato, Halkitis, & Orwat, 2013) consider health as their outcome 
variables. Understanding a behaviour using theories explaining behavioural 
outcomes, in addition to theories explaining health outcomes, allows for informed 
and integrated practice. This facilitates health promotion activities that are most 
likely to be successful.  
The theories highlight a number of key factors, from broad social influences 
at a societal and cultural level, to individual one-on-one interactions. Here, minority 
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stress theory considers external prejudice and discrimination (Meyer, 2003) and both 
biopsychosocial theory and the determinates of health theory consider social 
expectations and norms, peer influences and economic influences (Engel, 1980; 
Marmot, 2005). In the context of social cognitive theory these broad social 
influences fall into the category of environment (Bandura, 1998). Essentially, 
societal level and individual level social influences impact both the behaviours 
within chemsex and the health outcomes associated with chemsex.  
The next key influence which is considered in each of the models is biology 
or bio-medical factors, and in the context of social cognitive theory, biological 
factors are considered a sub-category within personal factors. Biological factors look 
at physical risk factors around vulnerability to disease. This includes the physical 
bio-medical transfer of HIV and STIs, the physical effects of substances, side effects 
of medications and any pre-existing medical conditions. Each of these can have an 
impact on social, psychological and behavioural influences which may influence 
behavioural or health outcomes.  
Next, each model incorporates psychological and/or behavioural aspects in 
addition to the behavioural outcomes associated with bio-psychosocial and social-
cognitive theory. Psychological factors may include mood, affect, personality, 
education, intelligence, and susceptibility to social influence, among many others 
(Engel, 1977; Pincus, Burton, Vogel, & Field, 2002). Most parts of minority stress 
theory are categorised here, among psychological and behavioural factors. These 
factors include expectations of rejection and internalised homophobia (Meyer, 2003). 
Social cognitive theory incorporates cognitive and affective influences under 
‘personal’ (Bandura, 1998). A practical example of how each of these factors might 
influence a case, is that of a new HIV diagnosis. This is likely to have an impact on a 
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person’s psychological wellbeing in terms of coping and rationalising - they may go 
through a grief like process. A new HIV diagnosis is likely to impact a person 
socially, as they share the news with friends and family, and what it means for them. 
It is also likely that a new HIV diagnosis will change a person’s behaviour, 
potentially for better or for worse (R. Holt et al., 1998). 
While each of these theories offer something unique and fundamentally 
helpful when looked at individually, their overarching ideas are helpful from a public 
health and health promotion perspective: considering the interplay between 
psychological (including behavioural) influences, social influences and biological 
influences. In addition, looking at a number of models, helps to understand chemsex 
both from a behavioural outcomes perspective and from a health outcomes 
perspective. While it is simplified, the diagram below allows a look at the similarities 
between the four theories.  
                
Figure 1. Similarities between the four theories that inform this applied research 
 
Health Promotion and Harm Reduction 
Health promotion targets a number of different aspects of the identified 
models. Health promotion has been defined by E. Green (1999) as “Any planned 
combination of educational, political, regulatory, community and organisational 
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supports for actions and conditions of living that contribute to the health of 
individuals, groups or communities” (p. 14). Health promotion takes many forms, 
but the average person’s exposure to health promotion comes in the form of 
advertising, screening tests, work or school-based education programs and provision 
of resources such as condoms and toothbrushes (Merzel & D’Afflitti, 2003).  
Harm reduction is a type of health promotion. It seeks to improve people’s 
conditions of living while fully acknowledging the limitations of social, economic, 
mental and other disadvantages. Harm minimisation began in the 1960s with activists 
and doctors opposing the criminalisation of substance use (Roe, 2005). In the 1970s 
and 1980s harm reduction work moved into the prevention of HIV/AIDS among 
injecting drug users (World Health Organization, 2004). Harm minimisation is an 
overarching term that seeks to reduce the overall harm caused by behaviours and 
practices that are detrimental to health – usually in the context of drug use. Harm 
reduction is one element of harm minimisation. It seeks to reduce harms without 
aiming to reduce usage, for example needle and syringe programs which aim to 
reduce the harm caused by drug use but do not seek to reduce the amount of drug 
being consumed (Ritter & Cameron, 2005).  
In the context of chemsex, health promotion aims could encourage abstinence 
from substance use and abstinence from any sexual activity that could result in HIV 
or STI transmission. However harm reduction acknowledges that the most ‘ideal’ 
behaviours are often unrealistic and seeks to reduce some of the dangers of higher 
risk behaviours (Ritter & Cameron, 2005). This acknowledges many of the 
psychological and social factors that influences a person’s behaviour. Harm 
reduction for chemsex involves targeting a number of different issues, primarily STI 
transmission and substance use. Harm reduction for STI transmission also tends to be 
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split into HIV prevention and secondarily other STI prevention. The key harm 
reduction tools for chemsex are condom use (Holmes, Levine, & Weaver, 2004), 
PrEP and frequent STI testing (Bourne, Reid, Hickson, Torres-Rueda, Steinberg, et 
al., 2015). Each of these interventions are impacted by levels of health literacy, 
psychological motivations and perceptions of risk, social expectations and individual 
responses to those expectations (Ayala et al., 2013; Peng et al., 2017).  
 Harm reduction for drug use includes strategies such as pill testing for 
content and additives (Cole et al., 2011). Use of single use injecting tools tends to be 
the most well-known harm reduction tool, as this is effective for preventing a number 
of BBV (Ritter & Cameron, 2006). Organisations in Australia and overseas are still 
campaigning for the decriminalisation of use or possession of small amounts of illicit 
substances (Cowdery, 2017). This is considered to be harm minimisation. These 
practices and campaigns can also be viewed in light of social determinants of health. 
The laws and politics that allow or prohibit these kind of public health campaigns, 
have a significant impact on behavioural and health outcomes (Saleemi, Pennybaker, 
Wooldridge, & Johnson, 2017; Zajdow, 2016).     
Some harm reduction strategies begin within the community, while others 
were first implemented as a result of scientific advances, such as PrEP 
(Daskalopoulou et al., 2014). Harm reduction aims to work with what a person can 
do or is willing to do and, as a result, some strategies are much less effective than 
others. For example an injecting drug user may be very willing to use clean injecting 
equipment but unwilling to reduce how often they are using (Beyrer, Sherman, & 
Baral, 2009).       
Each of these areas of harm reduction is encapsulated by the Ottawa Charter, 
which is a directive on what health promotion and harm reduction is and how it 
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should be implemented. The Ottawa Charter outlines a number of areas of 
intervention for health systems to implement for improved health outcomes. These 
areas include: Creating supportive environments, reorienting health services, 
strengthening community action, developing personal skills and supporting people 
through enabling, mediating and advocating (Potvin & Jones, 2011; WHO, 1986). 
The health promoting behaviours specifically investigated in this study are 
CAI with serosorting (the practice of using HIV status as a decision-making point in 
choosing sexual behaviour), PrEP use, adherence to antiretrovirals (ARV) as 
measured by viral load, regularity of HIV/STI testing, frequency of drug use and 
frequency of engaging in chemsex.  
Because of the multi-level interplay between these factors in chemsex, in the 
current study, participants are asked about their participation in each of these 
behaviours. The purpose of the present study was to answer a number of key 
questions about chemsex in Queensland for the industry partner, QuAC. They 
required some quantitative data about the nature of the chemsex that is occurring in 
Queensland, in order to design the most effective health promotion and HIV 
prevention campaigns, target clients effectively and identify the extent of the 
problem and risk factors.   
 There is a long history of health promotion within the gay and bisexual 
community, including other MSM, and those in the community are repeatedly 
exposed to cues to action in the form of health promoting behaviours (Leonard et al., 
2015; Mail & Safford, 2003). The most salient of these is condom use and frequent 
STI testing (Mail & Safford, 2003). However, in the last twelve months these have, 
in some contexts, been taken over by the messages to ‘come PrEPed’("Queensland 
AIDS Council 15/16 Annual Report," 2016; Queensland AIDS Council, 2017). 
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Trials throughout Australia have been branded under a number of names such as 
EPIC-NSW and PrEPX (Australian Federation of AIDS Organisations, 2017). Trials 
are in place to establish the effectiveness of PrEP in Australia in terms of cost 
effectiveness, adherence, safety and effectiveness of PrEP for HIV prevention in a 
‘real world’ sample (D. Russell, 2016). The advent of this new medication is being 
hailed by some as the ‘gay man’s contraceptive pill’ (Myers & Sepkowitz, 2013). 
PrEP is the use of antiretroviral medication by an HIV negative person to stop them 
acquiring the virus (McCormack et al., 2016). While in this study, Australian 
campaigns are of most interest, there is one international campaign worth noting. The 
#PREPforLove campaign was created in Chicago (USA) and it puts a positive spin 
on some of the negative language around HIV. Their slogan is “Love is contractible. 
Lust is transmittable. Touch is contagious. Catch feelings, not HIV.” While not 
discounting the risks associated with other STIs the #PREPforlove campaign 
emphasis’ the positive mental health effects of knowing you are protected from 
contracting HIV (Pickett, 2017). These campaigns are the next logical step in health 
promotion for HIV. A successful health promotion for chemsex could build on the 
momentum of the PrEP campaign, particularly given that PrEP is likely to be a big 
part of harm minimisation for chemsex, in addition to other health promotion 
activities and campaigns that target some of the specific chemsex behaviours.     
History of Drug Use and Interventions within the LGBTIQ Community  
Bars and pubs were for the most part, the main places where historically 
LGBTIQ people first felt accepted or free to be themselves. This has resulted in these 
venues playing a significant role in community connections. Strong affiliation with 
gay culture has been shown to increase the likelihood of drug and alcohol use and 
misuse (K. Green & Feinstein, 2012). Historically, and to a lesser degree, in the 
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present, LGBTIQ people have at times used substances to impede their inhibitions 
and act on same-sex desires (Race, Lea, Murphy, & Pienaar, 2017). At its broadest, 
the LGBTIQ community have high rates of alcohol and cigarette use (AIHW, 2011; 
Blosnich, Lee, & Horn, 2013). LGBTIQ people also have the highest 
methamphetamine usage of any specific group (AIHW, 2011). In fact, gay and 
bisexual men had three times the likelihood of reporting methamphetamine use 
compared to heterosexual men in the 2013 National Drug Strategy Household 
Survey (Roxburgh, Lea, de Wit, & Degenhardt, 2016).  All of these factors 
contribute to the need for effective interventions and harm reduction strategies. 
Issues experienced by LGBTIQ substance users can include issues around social 
roles, LGBTIQ specific depression and stress, peer and partner influences and 
pressures must be taken into account in order to appropriately treat LGBTIQ 
substance use (Hughes & Eliason, 2002a). Peer influences also play an important 
role in chemsex; with peers influencing decisions about which drugs to use, methods 
of ingestion and engagement in high risk activities whilst under the influence 
(Ahmed et al., 2016). Given this clear need for appropriate and effective 
interventions, the most recent National Drug and Alcohol Strategy 2016-2025 report 
has highlighted the substantial need for intervention within the LGBTIQ population 
(Roxburgh et al., 2016). The present study, which explores chemsex within 
Queensland, will help to inform health promotion practices within the Queensland 
AIDS Council who play a key role in health promotion and engagement of the 
LGBTIQ community, across a number of health areas including drug and alcohol 
use.  
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Current Perceptions of HIV and STIs and Risks  
 Perception of risk, primarily of HIV but also of other STIs, has changed over 
time within the MSM community. The AIDS epidemic of the 80’s resulted in 
extreme vigilance and fear, followed by a number of advances in the treatment and 
management of AIDS and subsequently HIV. These advances in medicine, over 
time, have resulted in increasing quality of life and extended lifespan. Public health 
campaigns have the challenging task of assuring those who are HIV positive that 
their condition is highly manageable and treatable with early diagnosis; whilst also 
encouraging safer sex and trying to minimise the spread of the disease, without 
creating undue stigma and oppression of those living with HIV. 
HIV optimism, that is, the decrease in perception of severity of HIV, has been 
hypothesised to result in an increase in high risk sexual behaviours (Van de Ven, 
Rawstorne, Nakamura, Crawford, & Kippax, 2002). A meta-analytic review found 
that while having an undetectable viral load did not increase high risk behaviours, 
both HIV positive and negative people whom had reduced concerns about engaging 
in unsafe sex, because HIV treatments are readily available and effective, were more 
likely to engage in these high risk sexual behaviours (Crepaz, Hart, & Marks, 2004). 
From the framework of the Health Belief Model, this is considered a reduction in the 
perceived threat of HIV. Albarracin et al. (2005) performed a meta-analysis of a 
number of health behaviour theories and interventions based on them. Their 
discussion only tangentially supports the idea that reduced perception of threat has 
resulted in reduced condom use. Overall, other predictors, as discussed in a number 
of health behaviour model, such as perceived behavioural control and actually 
behaviour skills (knowing how to ask for condom use) are much better predictors of 
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this behaviour (Albarracin et al., 2005). So while HIV optimism has some effect, it’s 
not a key driver of changed behaviour.   
Another key concern, is the risk of hepatitis C transmission. Hepatitis C is 
generally considered to be of most burden to injecting drug users (Garfein et al., 
1998), this is a key concern in the chemsex discussion, those who inject their 
‘chems’ are most at risk. However, hepatitis C has also been known to be transmitted 
via sexual activity. While HIV positive people have increased susceptibility to the 
virus (Page & Nelson, 2016), HIV negative men engaging in higher risk sexual 
practices are also at risk (McFaul et al., 2015). An English study found 14.8% of 
HIV negative men who came for sexual health screening were positive for hepatitis 
C, only 20.5% of these men were injecting drug users (McFaul et al., 2015). While 
hepatitis C is now more ‘curable’ now than HIV, up until recently, the treatments 
were long and often not well tolerated. Recent advances in hepatitis C medications 
have resulted in shorter, more effective and are better tolerated treatments. However, 
they are expensive medications for governments to purchase (Hepatitis Australia, 
2015; NHS, 2015). Hepatitis A and B can also be transmitted via CAI and other high 
risk sexual activities (Hepatitis Australia, 2017). Both are vaccine preventable and 
the hepatitis B vaccine is on the national vaccine schedule (National Immunisation 
Program Schedule, 2016). Most people who contract hepatitis A experience a 
relatively short illness and recover (Cuthbert, 2001). However hepatitis B is treatable 
but not curable and has a chronic course. Other, more common STIs such as 
chlamydia, syphilis and gonorrhoea are easily treated but the growing threat of 
antibiotic resistance creates a growing public concern about the future of these 
treatments (WHO, 2016). Other illness such as cancers caused by the Human 
Papilloma Virus (HPV) are another risk of unsafe sex. HPV is the main cause of anal 
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cancer in MSM but the strains of HPV most likely to cause anal cancer are vaccine 
preventable (Machalek et al., 2012). However the vaccine was only offered to males 
under the national vaccination program from 2013 onwards. This means that men 
who finished high school before 2013 are less likely to be vaccinated (Immunise 
Australia Program, 2017).  
A number of the HIV positive participants in ‘The Chemsex Study’(UK; 
Bourne et al., 2014), who chose not to use condoms, were reportedly unconcerned 
about the risk of acquiring other STIs because there are effective and available 
treatments. While some participants reported being worried about acquiring hepatitis 
C, this concern did not translate into harm reduction behaviours (Bourne, Reid, 
Hickson, Torres-Rueda, & Weatherburn, 2015). Notably this research was conducted 
before newer hepatitis C treatments became widely available (NHS, 2015).     
Current risks associated with living with HIV. Medications and their side 
effects. Current guidelines for the treatment of people with newly diagnosed HIV 
(People living with HIV; PLWH) recommended the use of anti-retroviral 
medications (ART) regardless of the progression of the disease or their T cell count. 
T cell count is an immunological marker of a person’s level of infection and 
infectivity. These recommendations are made to reduce the impact on quality of life 
and to minimise the risk of disease transmission (US DHHS Guidelines with 
Australian commentary, 2016). Triple antiretroviral combinations are generally 
recommended in high income countries, such as Australia, because of their proven 
efficacy over mono and duo type therapies (Hogg et al., 2008). Previously mono or 
duo therapies were considered sufficient and treatments were generally only initiated 
when a CD4 cell count of below 350 cells per microlitre had been reached 
(McCullough, 2011; The HIV-CAUSAL Collaboration, 2011), although there has 
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been much professional debate around this issue for many years (McCullough, 
2011). After the collation and publication of three major randomised control trials 
which were conducted between 2001-2015 the decision was made to recommend the 
commencement of ART regardless of CD4 counts and with it the medial research 
reflected a full circle from the early years of ‘hit hard, hit early’ of the late 90’s to the 
present day approach of ‘hit hard, hit early’ (Eholie et al., 2016). This is reflected in 
the Joint United Nations Programme on HIV/AIDS (2015). They have set the 
challenge of 90-90-90 by 2020, and this has helped to spread the message that 
initiating proactive treatment early, or as soon as possible after diagnosis, is the most 
evidence based approach to treatment.  The 90-90-90 targets aim for, 90% of PLWH 
being aware of their status, 90% of those people being on effective treatment and 
90% of those people being virally suppressed (have an undetectable viral load).  
Some public health officials and the media recently declared the “End of AIDS?” 
(Sachs, 2016; The Lancet, 2015). However HIV as a chronic illness, with serious 
complications from long term ART use, is still a major public health concern (Deeks, 
Lewin, & Havlir, 2013). In addition, tertiary illness such as cardiovascular disease, 
kidney disease, liver disease, cancer, and some neurological diseases are known to 
result from long term use of ART, resulting in premature death as an indirect result 
of their HIV (Deeks et al., 2013). In addition to these factors, MSM continue to make 
up the majority of new HIV notifications and continue to be disproportionately 
affected, compared to other populations (Chow, Gamagedara, Bellhouse, & Fairley, 
2015). This is particularly true within an Australian context (M. Holt, 2017). While 
an enormous amount of progress has been made over the last 20 years in the ‘fight 
against AIDS’ and HIV has become a manageable condition, it is still an avoidable 
chronic illness that still warrants considerable work to reduce the number of new 
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notifications each year. At present there have been between 1000-1100 each year for 
the last five years (M. Holt, 2017).  
Transmitting the virus and being undetectable. Optimal adherence to HIV 
medications can result in an undetectable viral load (Chesney, Morin, & Sherr, 
2000). This means that there are so few replications of the virus in the body that it is 
undetectable on tests. This also means the virus is effectively untransmittable for as 
long as the individual maintains an undetectable viral load (Attia, Egger, Muller, 
Zwahlen, & Low, 2009). Through adequate medication adherence, viral suppression 
can be reached within the first 24 weeks of treatment, this is considered ‘optimal 
adherence’. Good practitioner-patient relationships, motivational interviewing and 
assessment of barriers such as pill size, pill numbers and daily routines have been 
shown to improve adherence (Lundahl et al., 2013; Nachega et al., 2014).  Poor 
adherence can lead to a number of treatment complications including, viral load 
becoming transmittable again and drug resistance resulting in reduced treatment 
options and poorer long-term prognosis (Chesney et al., 2000). This is pertinent in 
regard to the potential for extended chemsex sessions to interrupt a person’s 
medication schedule. Bourne et al. (2014) reported men having chemsex sessions 
that lasted up to four days. While these long sessions have a number of health 
implications, adherence to ARVs is one of the most prominent in terms of HIV 
transmission and prevention. This is one of the ways addressing issues within the 
chemsex scene could support the United Nations 90-90-90 goals. However, for some 
people, having an undetectable viral load may lead to decreased likelihood of using 
condoms and therefore increase the risk of other STI transmission, including 
hepatitis. Acquiring or passing on different strains of HIV may also be a concern for 
PLWH who have sub-optimal ARV adherence (Redd, Quinn, & Tobian, 2013). 
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Despite readily available treatments for both HIV and other STIs, some MSM may 
not be aware of the risks associated with the multiple differing strains of HIV. HIV 
co-infection or superinfection occur when one person acquires multiple strains of 
HIV (Redd et al., 2013). While the most prominent strain in Australia, and 
worldwide, is HIV-1, ‘M group’, there are a number of subtypes within the M group 
as well as three other subgroups as the same level as the ‘M group’. There are also a 
number of strains within the HIV-2 group. HIV-1 → M → B is the most common 
strain worldwide, and the most common antiretrovirals are created based on this 
strain.   
 In addition, people with HIV are already more susceptible to syphilis due to 
HIV medications (Rekart et al., 2017). Rekart et al. (2017) found that “highly active 
retroviral therapy [current first line treatment for HIV infection] have the potential to 
alter the innate and acquired immune responses in ways that may enhance 
susceptibility to T. pallidum (syphilis)”(p. 1). All of these factors must be considered 
in light of the social determinants of health (US Department of Health and Human 
Services, 2014).    
Life expectancy. Current life expectancy of MSM living with HIV is 
approaching that of HIV negative peers (Nakagawa, May, & Phillips, 2013). Early 
diagnosis and treatment is one of the leading causes of this optimistic life expectancy 
(Nakagawa et al., 2013). Nakagawa et al. (2012) report that, after controlling for 
other factors, MSM who are HIV positive should expect to live, on average, seven 
years less than HIV negative men. This of course assumes optimal adherence to 
ART. Population based samples (i.e., not just MSM) show that injecting drug users 
with HIV have shorter life expectancies than non-injecting drug users with HIV 
(Hogg et al., 2008). While Hogg et al. (2008) could not draw causal conclusions 
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about the reasons for this relationship they suggest that other known factors such as 
unequal access to treatment, hepatitis co-infection, socioeconomic status, smoking 
and alcohol use may all contribute to the discrepancy.   
PrEP and other harm reduction methods. Condoms. Condom use is 
reportedly low among those who regularly engage in chemsex in the Netherlands 
(Knoops et al., 2015). Participants cited a number of reasons including: poor fit and 
latex allergies, sexual activity being less enjoyable while using condoms and 
unsurprisingly, some participants reported that intentions to use condoms often 
become less salient after ingesting substances for the purpose of chemsex. Bourne et 
al. (2014) report that while some men neglect to use condoms when they had 
previously intended to use them, many also sought out condomless sex for a variety 
of reasons. Some MSM have stated that their HIV diagnosis was a relief because it 
meant they no longer needed to use condoms and no longer needed to worry about 
acquiring HIV (Heijman, Zuure, Stolte, & Davidovich, 2017).  
PrEP. PrEP is the same medication used by HIV positive people to treat HIV, 
just in slightly different combinations. When taken by HIV negative people it has 
been proven to prevent HIV infection (WHO, 2012). PrEP works by blocking the 
enzyme that allows HIV to reproduce in the human body (Anderson et al., 2012). 
While optimal levels of the drug are achieved by taking the medication once daily 
(resulting in 99% effectiveness against acquisition of the HIV virus if exposed to it), 
taking four PrEP pills within a seven day period will still result in a 96% reduction in 
HIV risk (Anderson et al., 2012). PrEP was first available in the USA in 2012 and 
has been available in Australia since May 2016, however access is currently 
restricted to those who are eligible for clinical trials or can afford to import it from 
overseas, as it is not currently available on the pharmaceutical benefits scheme (PBS; 
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Lewin & Wright, 2016). Intermittent use of PrEP has also been a consideration, not 
just for sub-optimal adherence but also for men who wish to use it for a number of 
days or weeks while on holiday or when attending LGBTIQ events such as Mardi 
Gras or other heavily sexualised events (Elsesser et al., 2016). In an American study 
of more than 7000 participants, 92.6% reported that taking PrEP daily was a barrier 
to its use. However men who reported having gone on a sex-based vacation in the 
last 12 months had greater odds of reporting that they would take PrEP for short 
periods if it was effective as an intermittent medication, compared to men who had 
not gone on vacation with the explicit purpose of engaging in sexual activity 
(Elsesser et al., 2016). PrEP needs to be taken for at least seven days in order to have 
therapeutic efficacy, which for most people is a viable option if they want the 
protection for a sexualised vacation or holiday (Center for Disease Control and 
Prevention, 2014; Mascolini, 2014). Continued PrEP use is recommended for 
sterodiscordant couples and for people having regular CAI (Wright et al., 2017).   
Around the world, access to PrEP has been associated with decreased stigma 
around its use (Ayala et al., 2013) . However some factors decrease how acceptable 
participants found PrEP to be. Some of the reported barriers to use were cost, 
perceived efficacy and potential side effects including nausea, headaches and weight 
loss (Ayala et al., 2013). These barriers were also found in a recent meta-analysis 
(Peng et al., 2017). Additional barriers to PrEP use were adherence and stigma, 
(Peng et al., 2017).  Peng et al. (2017) found that younger, wealthier and better 
educated MSM were most likely to report PrEP as an acceptable method of HIV 
prevention. Men who found PrEP acceptable were also more likely to have 
previously used post exposure prophylaxis (PEP; a month long course of medication 
taken after exposure or likely exposure to the HIV virus after condom breakage, 
CHEMSEX  21 
needle stick injury, sexual assault etc.), have more frequent sexual acts and higher 
numbers of sexual partners (Peng et al., 2017). These last two reasons, are 
noteworthy features of chemsex (Bourne et al., 2014; Bourne, Reid, Hickson, Torres-
Rueda, & Weatherburn, 2015). While the primary purpose and proven efficacy of 
PrEP is to prevent HIV from replicating in the human body and causing HIV 
infection, there is also some limited evidence to suggest it has some utility against 
the hepatitis B virus and herpes simplex virus (Andrei et al., 2011; Lewin & Wright, 
2016; Piliero & Faragon, 2002).   
Serosorting. Serosorting is a term used to describe the behaviour of choosing 
to have sexual contact with people of the same HIV status. While logical, this 
method of harm reduction has a number of flaws. The main problem with serosorting 
is the window between when an individual is infected with HIV and when they test 
positive for the virus. There can be a period of between a one to two weeks to two to 
three months when a person can transmit the virus but it is not detected on standard 
tests (British HIV Association, 2008; Rosenberg, Pilcher, Busch, & Cohen, 2015). In 
addition, and this is particularly true for men with a lot of partners or frequent sexual 
encounters, even testing every three months may not be sufficient to detect the virus 
before it is transmitted to a partner (Rosenberg et al., 2015). Some of the problems 
have been lessened with medical advances, however it remains an imperfect method 
of reducing HIV transmission due to the aforementioned concerns (Kurtz, Buttram, 
Surratt, & Stall, 2012). 
Serosorting has also been known to increase stigma around being HIV 
positive (Golub, Tomassilli, & Parsons, 2009), particularly up until suppression of 
the virus to undetectable levels was possible through medical advances (Van Den 
Boom et al., 2013). Men who did disclose their positive status may have been 
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shunned from some social groups or excluded in other ways (Smit et al., 2012). In 
the context of chemsex, research has indicted that serosorting is used within chemsex 
sessions (Knoops et al., 2015). Bourne, Reid, Hickson, Torres-Rueda, and 
Weatherburn (2015) reported that eight out of 13 HIV positive men in their sample 
reported always engaging in serosorting during chemsex. However they highlight 
that, HIV status was at times, assumed rather than explicitly discussed. This evidence 
indicates that while these men are choosing to engage in harm reduction practices, 
they are choosing one of the least effective methods. Bourne, Reid, Hickson, Torres-
Rueda, and Weatherburn (2015) report that the main reason cited for wanting CAI 
was increased physical sensation. This is a commonly cited reason for not using 
condoms, and one that must be addressed in order for harm reduction to be most 
effective.  
Chemsex 
As previously mentioned, the concept of chemsex places an emphasis on 
premediated or planned consumption of drugs for the purpose of then engaging in 
prolonged or heightened sexual behaviour. This may include consuming substances 
before and/or during sexual activities but is distinct from deciding to have sex once 
intoxicated. Much of the existing research on chemsex, focuses on the use of 
stimulants and high risk behaviours, such as unprotected anal intercourse. Drugs 
such as crystal methamphetamine, GHB/GBL and mephedrone are most prominent 
(Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2015; Knoops et al., 2015). 
While the use of non-stimulant drugs and sexual enhancement drugs such as 
Sildenafil (Viagra) and Amyl Nitrate used on their own, are technically included in 
the definition, they are not the primary focus of chemsex literature. However they are 
commonly used with stimulants to enhance the functioning of sexual organs. 
CHEMSEX  23 
Research on chemsex in Australia is extremely limited. However there is an 
abundance of research on MSM and their drug use, both in general and specific to 
the sexual context. Hopwood, Lea, and Aggleton (2015) and Lea et al. (2016) 
examine general drug use within the MSM community, with Hopwood et al. (2015) 
reporting 90% of their respondents injecting drugs in a sexual context, with the most 
popular drug being crystal methamphetamine. As is evident, there are a plethora of 
public health concerns relating to chemsex (Bourne, Reid, Hickson, Torres-Rueda, 
Steinberg, et al., 2015).  
Motivations and values associated with chemsex. MSM have reported a 
number of motivating factors for engaging in chemsex, the first of which is the 
ability and freedom to engage in the kind of sex they desire (Race et al., 2017; 
Weatherburn, Hickson, Reid, Torres-Rueda, & Bourne, 2016). Some of the features 
of ‘the sex that is wanted’ are: increased libido, confidence, disinhibition and stamina 
(Weatherburn et al., 2016). While there is limited research looking at ‘chemsex’ 
motivations specifically, there is ample research describing sexualised drug use by 
MSM, dating back more than ten years (Kurtz, 2005; D. McKirnan, D.  Ostrow, & B. 
Hope, 1996; Mullens et al., 2009). Hurley and Prestage (2009) reported that one of 
the key motivations they identified in relation to intensive sex parties was the 
‘maximisation of sexual pleasure’. Mullens, Young, Dunne, and Norton (2011b) 
reported a quantitative analysis of the perceived effects and benefits of a variety of 
substances. These included cognitive impairment, improved sexual activity and 
improvement in social engagement, among others.   
While the majority of motivations and values reported are viewed within a 
positive light, Kurtz (2005) reported a much more pessimistic view of sexualised 
drug use. They suggested that the use of crystal methamphetamine by MSM was 
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used to escape loneliness to deal with feelings of being unattractive and to reduce 
sexual inhibitions. While these are all mentioned in passing in more recent research 
(Weatherburn et al., 2016), they appear to be less prevalent, or at least, less 
emphasised. Mullens et al. (2011b) reported that each of the perceived effects of a 
variety of substances tended to differ for differing types of substances however, a 
variety of individuals tend to report similar desirable effects from a single substance, 
for example multiple people may report that crystal methamphetamine increases 
libido (Mullens et al., 2009). In discussing the motivations behind the behaviour it 
can be easy to pathologise or criticise the desire for heightened pleasure or 
disinhibition, particularly in light or some of the associated high risks (Hurley & 
Prestage, 2009). However in order to reduce risks, it is important to acknowledge the 
perceived benefits, and validate these desires and their normative contexts.        
Norms and social context. Ahmed et al. (2016) reported that more than half 
of their sample believed 70-90% of gay men ‘on the scene’ engaged in drug use; and 
that chemsex is considered to be a normative behaviour. These perceptions are 
despite 8.3%, 16.5%, and 12.5% reporting having ever used crystal 
methamphetamine, mephedrone, and GHB/GBL, respectively, in an English sample 
(Hickson, Reid, Hammond, & Weatherburn, 2016). For comparison, the most recent 
Gay Community Periodic Survey (GCPS), a large community survey of gay men’s 
sexual and general health and wellbeing, indicated 9% of participants had used 
crystal methamphetamine in the previous six months and 3.9% using GHB in the 
same period. The GCPS did not report use of mephedrone (Lee et al., 2016). 
Obviously the differences between measures of lifetime use versus six monthly use 
make it difficult to compare these differing findings. Participants in England and 
Denmark reported that much of their own drug use, and specifically chemsex 
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behaviours, occurred in private homes, during sex parties facilitated with the use of 
geospatial apps (Ahmed et al., 2016; Knoops et al., 2015). Some of the apps on the 
markets at present are Grindr, Squirt and Hornet. Most are free to download and use. 
 These private parties, often facilitated by apps, contribute to the perception 
of normalised sexualised drug use (Knoops et al., 2015). Ahmed et al. (2016) 
reported that a number of men in their focus groups reported exchanging sexual 
activities for illicit substances or vice versa. Geospatial apps play a significant part in 
the facilitation of these encounters and exchanges. Like many things facilitated by 
new technology, sex parties and ‘hook ups’ have been present among MSM for many 
years. However the apps provide for these age old practices to happen quickly and at 
greater volume than in times before smart phones (Miles, 2017). Some of these apps 
also allow sexual sessions to be filmed and broadcast live, a feature much less 
accessible before smart phones (Tziallas, 2015). While there are no statistics on 
exactly how prevalent chemsex is, all these factors influence the normalisation of a 
behaviour that, while common (Lee et al., 2017), is perhaps not has prevalent as the 
geospatial sex apps would have you believe. 
Ahmed et al. (2016) reported a perception that PLWH were more likely to 
engage in higher risk behaviours such as ‘slamming’ (injecting drug use), CAI and 
crystal methamphetamine use, primarily because they have ‘nothing left to lose’. 
Implied in this is the notion that having HIV is the worst result of these behaviours 
and nothing could be worse. A number of authors also comment on the differing 
social expectations of injecting drug use, or ‘slamming’ (Ahmed et al., 2016; Amaro, 
2016; Knoops et al., 2015). For some MSM, injecting drug use is considered a hard 
line they will not cross, while for others it is commonplace and expected (Knoops et 
al., 2015). Both groups are aware of these subgroups within their communities. 
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These preferences are often communicated with subtle codes within geospatial apps 
(Knoops et al., 2015). In spite of these hard limits established by some chemsex 
participants, peer pressure is readily available and users are encouraged to push 
boundaries further and begin ‘slamming’ (Knoops et al., 2015). 
Risks to mental health. Bourne, Reid, Hickson, Torres-Rueda, and 
Weatherburn (2015) reported that men whom committed to always using condoms 
during chemsex felt more psychologically secure because they knew they were 
mitigating the risk of either transmitting or acquiring an STI. However Bourne et al. 
(2014) also reported an attitude of ‘dammed if you do, dammed if you don’t’ towards 
many elements of chemsex including drug use and condom use. This is related to the 
‘relief’ described by some after a new HIV diagnosis. Specifically, some men have 
reported a sense of relief of no longer having to worry about acquiring HIV, after 
having been diagnosed, and felt that diagnosis was a reason to relax their safer sex 
practices (Heijman et al., 2017). These examples summarise the complex 
relationships between engaging in enjoyable sexual activity and the same behaviour 
that often steps into disregard or intentional suppression of thoughts about the risks 
(Bourne & Weatherburn, 2017). Chemsex seems to span across the spectrum from 
men who engage in the behaviour for pleasure while also engaging in all reasonable 
levels of risk reduction – condom use, PrEP use, drug testing and clean tools – 
through to the men who engage in chemsex to numb the pain of HIV fear, 
discrimination, shame and internalised homophobia, as well as possible 
intersectionality with other disadvantage (Bourne et al., 2014; Knoops et al., 2015). 
The comparatively poorer mental health of the LGBTI population compared to the 
general population is well established (King et al., 2008) and the subject of research 
and intervention. As such it can be difficult to separate out the effects of sexualised 
CHEMSEX  27 
drug use on mental health compared to generally poor mental health (Race et al., 
2017).  
HIV transmission risks. The majority of ‘slammers’ only use needles once 
and do not share. However there is a small subset within the slamming community 
who intentionally share needles, not out of necessity, but as “the ultimate form of 
connectedness” (Knoops et al., 2015, p. 31). However this behaviour is generally 
disapproved of by other ‘slammers’ who have taken heed of the many year of harm 
reduction work in needle and syringe exchange programs (Knoops et al., 2015).   
Drug use in chemsex. Some men in The Chemsex Study (UK) reported that 
the use of drugs, specifically crystal methamphetamine, made them more likely to 
disregard risks associated with CAI and/or high risk sex acts such as fisting (the 
insertion of one partner’s entire hand into the other partner’s rectum for sexual 
pleasure), bondage, watersports (sexual activity involving urination) or group sex 
(Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2015). While a causal 
relationship has not been established, there is some evidence to suggest that use of 
crystal methamphetamine is detrimental to PLWH on a chemical level. Ellis, 
Childers, Cherner, and The HIV Neurobehavioral Research Center Group (2003) 
reported that people on ARVs for HIV treatment who also used crystal 
methamphetamine had more replications of the HIV virus, than controls. 
Poly-drug use. Knoops et al. (2015) reports that nearly all their participants 
used erectile-dysfunction drugs prior to or during chemsex to help maintain an 
erection. Users reported taking erectile-dysfunction drugs either because crystal 
methamphetamine inhibited their ability to maintain an erection during the course of 
chemsex, or men used the medications to maintain the erection for an extended 
period of time. Combining crystal methamphetamine with other illicit drugs such as 
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GHB, ecstasy or mephedrone, was also reported as common. Poly drug use has been 
associated with increased levels of CAI, in addition to other heightened risk 
behaviours (Daskalopoulou et al., 2014). Bourne et al. (2014) reported that in the UK 
The Chemsex Study “Poly drug use is the norm, with few drug users using only one 
drug” (p. 30).  
Extended sexual session times. A key feature of chemsex is the extended 
time frames, with sexual activities lasting from a few hours to a few days. The longer 
events are facilitated by the effects of substances such as stimulants, with sex 
enhancing drugs making sexual intercourse over many hours possible. This creates a 
risk over and above the issues associated with drug use and sexual health issues 
during shorter time frames. Chemsex participants have noted issues associated with 
drug use in these extended time periods including sleep deprivation, and lack of 
nutrition and fluids (Bourne et al., 2014; Knoops et al., 2015). However, the public 
health focus is concern around adherence to ARV, either PrEP or HIV treatment 
regimes. While suboptimal adherence to PrEP still provides a reasonable level of 
protection (four pills in seven day is 96% effective where seven pills in seven days is 
99% effective), in conjunction with high risk sexual practices even small increases in 
risk of HIV transmission are cause for concern (Anderson et al., 2012). Prolonged 
sexual activity can cause abrasions and other damage to the rectum, which increases 
the likelihood that HIV can enter and replicate in the body of an HIV negative person 
(Baggaley, White, & Boily, 2010). The use of Sildenafil also increases this risk by 
making sexual intercourse over many hours possible (Crosby & Diclemente, 2004). 
PLWH also face significantly increased risk from extended chemsex sessions. 
Reback, Larkins, and Shoptaw (2003) report that use of crystal methamphetamine 
over a number of days has been associated with non-adherence to ARVs. This non 
CHEMSEX  29 
adherence can be either planned or unplanned. Men will sometimes acknowledge 
they are going to be intoxicated and make a decision not to take their medication for 
several days; Or they do not make plans in advance and as a result do not take their 
medication for the duration of their intoxication. While HIV transmission is a risk 
during these times, the development of drug resistance is also a major concern 
(Reback et al., 2003).  
Demographic Characteristics Expected to Influence Chemsex 
Age. Age is a key variable and often expected to have an impact on 
participant’s behaviours. It is likely there will be differences in age between those 
who engage in chemsex, those who engage in CAI while intoxicated and those who 
do not engage in these behaviours. In public health research, age is often associated 
with differing sexual behaviours, and research will adjust for age accordingly. 
Knowing if and where these age differences occur is helpful in planning 
interventions. Bourne et al. (2014) interviewed 30 MSM who all engaged in 
chemsex, these men had a mean age of 36 and a range of 21-53. Knoops et al. (2015) 
reported an age range of 23-60 years with a mean of 42.8. Sewell et al. (2017) 
reported that men aged less than 30-39 years were most likely to be engaged in 
chemsex drug use. It is expected that this age bracket of men in their 30’s will be 
most likely to engage in chemsex and CAI while intoxicated in the present study. 
Age is also a noteworthy variable because young MSM account for that largest 
proportion of new HIV diagnosis each year (The Kirby Institute, 2016).       
Sexuality. While directionality is not hypothesised, it is expected that there 
will be differences between those who identify as homosexual versus those who 
identify as heterosexual or bisexual. The mechanism for these differences may be 
differing levels of engagement within the LGBTIQ community, peer influences 
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and/or unknown mechanisms. There is evidence (M. Friedman et al., 2014) to 
suggest that bisexual people sometimes have worse health outcomes than their 
homosexual peers.     
Place of residence. While drug use within the general community is slightly 
more prevalent within rural and regional areas of Australia (National Rural Health 
Alliance, 2015). Male same sex couples are more likely to live in cities (Australian 
Bureau of Statistics, 2013) and are therefore more likely to have more access to sex 
on premises venues (SOPV) and private venues for chemsex, than those who live in 
regional or rural areas. As such it is expected that more of the men living in cities 
will be reporting engagement in chemsex.   
The Present Study 
The aim of the present study was to establish key characteristics of chemsex 
in Australia, with a focus on SEQ, in an exploratory and descriptive manner. The 
research on chemsex, to date, has been based largely on populations in the United 
Kingdom (Bourne et al., 2014; Sewell et al., 2017)  and Europe (Knoops et al., 2015; 
Schmidt et al., 2016), with a few studies in parts of Asia (Lim et al., 2015). The 
research was undertaken to provide Australian specific data to Queensland AIDS 
Council (QuAC) on the extent of chemsex within Queensland and Australia, and to 
help inform appropriate areas for future intervention and health promotion. QuAC 
were an industry partner in this project and the data is primarily intended to provide 
detailed information to assist with developing prevention, health promotion and harm 
reduction materials. It is hoped that the present study can help to inform future health 
promotion and harm reduction strategies in a real world context. 
All hypotheses that use the term “CAI” refer to the variable that asked 
participants “Have you had condom-less anal sex in the past 12 months with any 
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partners of unknown or serodiscordant status whilst drunk or high?” This is a salient 
risk factor for HIV and STI transmission. 
The first aim is to report on current rates of drug use and sexual activity 
among people who report engaging in chemsex. It is hypothesised that people who 
do engage in chemsex will be significantly different from those who do not engage in 
chemsex on sexuality, gender, age, Aboriginal or Torres Strait Islander status, place 
of birth, place of residence, ethnic background, HIV status, STI rates, reports of CAI, 
HIV testing recency, and PrEP use (Hypothesis 1). One of the key chemsex drugs 
(crystal methamphetamine, GHB or mephedrone) will have more of an influence on 
CAI than the others. (Hypothesis 2). It is hypothesised that longer chemsex sessions 
will increase the likelihood of participants engaging in CAI (Hypothesis 3). It is 
hypothesised that the combination of ARV use and chemsex will be associated with 
more CAI. (Hypothesis 4). It is predicted that chemsex will be associated with an 
increase in CAI which will increase the risk of acquiring non HIV, STIs due to the 
use of antiretrovirals (undetectable or on PrEP )(Hypothesis 5).  
 
Method 
Participants 
The total sample comprised of 663 MSM, 644 (97.1%) identified as male and 
16 (2.5%) identified as trans and 3 (0.5%) identified as non-binary. See Appendix D 
for an explanation of gender identity. Participants ranged in age from 18 years to 
over 80 years, with the mean age falling into the 30-39 years range. As per the ethics 
application (Appenxidx A), participants were recruited via convenience sampling 
from community settings such as gay clubs, community events, LGBTIQ online 
spaces and visitors to Queensland AIDS Council premises in response to flyers 
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calling for participants (Appendix C). Cisgender women were excluded from the 
study. Recruitment targeted MSM, particularly those who engage in drug use. 
Participants included trans men who have sex with men and trans women who have 
sex with men. There were 516 (77.8%) participants whom identified as gay or 
homosexual, 119 (17.9%) identified as bisexual, 14 (2.1%) identified as 
heterosexual, six (0.9%) identified as pansexual, eight (1.3%) identified as another 
sexuality such as ‘queer’ or ‘homoflexible’. Most participants identified their 
ethnicity as Australian (n = 512, 77.2%) and were born in Australia (n = 540, 
81.4%). A further breakdown of ethnicities indicated that 85% identified their 
ethnicity to be from a country in the Asia-Pacific, with the next biggest group 
identifying ancestry from within Europe (7.2%). Please see Table 1 for further 
details. Attempts were made to identify participants who reported ancestry from 
countries with high HIV prevalence. However there were less than 20 participants 
who identified as being from North East or South East Asia or Sub-Saharan Africa, 
which are higher HIV endemic countries. The study included a number of Aboriginal 
and Torres Strait Islander participants (n = 49, 7.5%), at a rate slightly higher than 
the population rate reported by the Australian Bureau of Statistics (ABS; 4.2% in 
QLD). The majority of participants lived in cities (n = 508, 76.6%), with about one in 
five participants living in regional or rural areas (n = 104, 15.7%; n = 27, 4.1%). Of 
those participants who reported their HIV status and time of their last HIV test, who 
reported as negative or unknown, one sixth (n = 101, 16.8%) reporting having tested 
in the last month and more than a third reporting having tested in the last 1-6 months 
(n = 199, 33.1%). Twenty-Seven participants (4.5%) tested more than four years ago 
and 16% (n = 96) reported having ‘never tested’. Under 10% of participants reported 
being HIV positive (n = 62, 9.4%), and 10.9% (n = 72) reported ‘not knowing’ their 
CHEMSEX  33 
status. A small number (3.5%) did not answer this question regarding HIV status. Of 
those who reported being HIV positive, 88.7% (n = 55) reported having an 
undetectable viral load with seven participants (11.3%) reporting a detectable viral 
load. Of those who did not report being HIV positive (participants who reported 
being negative, unknown or did not answer the question), 11.6% (n = 70) reported 
current PrEP use, 67 of these reported their status as negative, three reported their 
status as unknown. None of the participants who did not report their HIV status 
reported being on PrEP. Due to the sensitive nature of the material in the study, as 
per the ethics application (Appendix A) most questions were not compulsory. As a 
result, there are small amounts of missing data for each question. Of the collected 
data of 671 cases, two were cisgender women, who were removed from the data set. 
Six other cases were removed due to blank or severely inconsistent responses. Those 
who did not respond to the question “Have you engaged in chemsex in the last 12 
months?” were different on a number of variables, see Results for full details. There 
were 582 participants who provided data on this question. There were 81 participants 
who did not provide a response to this question and therefore were excluded in the 
predictive analyses. They were however included in the descriptive analyses of 
overall drug use, STIs and other sexual risk questions.  
 Design 
The current study adopted a cross sectional prospective sampling design with 
a single point of data collection. It used a descriptive and exploratory data analysis to 
guide future prevention and health promotion. The design was informed by a request 
for specific information on the chemsex practices within the LGBTIQ community at 
this point in time. This was required to help inform future health promotion and 
prevention efforts.  
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Table 1 
Demographic characteristics of participants 
 n % 
Gender   
Male  644 97.1 
Trans*/Other 19   2.9 
Sexual Orientation   
Gay/Homosexual 516 77.8 
Bisexual 119 17.9 
Heterosexual 14 2.1 
Pansexual 6 0.9 
Other 8 1.3 
Age   
18-29 198 29.9 
30-39 153 23.1 
40-49 148 22.3 
50-59 103 15.5 
60-69 43 6.5 
70-79 15 2.3 
80+ 3 0.5 
Ethnicity   
Anglo-Australian 512 77.2 
Other 151 22.8 
Ethnicity as derived from free text responses   
Asia-Pacific region  573 86.5 
Europe 48 7.2 
Asia 21 3.2 
South America 9 1.4 
North America 5 0.8 
Africa 4 0.6 
Other/Unknown 3 0.5 
Country of Birth   
Australia 540 81.4 
Overseas  111 16.7 
Not reported 12 1.8 
Aboriginal and Torres Strait Islanders   
Aboriginal 29 4.4 
Torres Strait Islander 17 2.6 
Aboriginal and Torres Strait Islander 3 0.5 
Place of Residence   
Urban/City 508 76.6 
Regional 104 15.7 
Rural/Remote 27 4.1 
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Table 2 
Other relevant characteristics of participants 
 n % 
Last HIV test (if not HIV positive)    
1-4 weeks ago 101 16.8 
1-6 months ago 199 33.1 
7-12 months ago 74 12.3 
1-2 years ago 52 8.7 
2-4 years ago 27 4.5 
More than 4 years ago 27 4.5 
Never tested 96 16 
Not reported 25 4.2 
HIV status   
Positive 62 9.4 
Negative 506 76.3 
Unknown 95 14.4 
Last Viral Load test if HIV+   
Undetectable 55 88.7 
Detectable 7 11.3 
PrEP use (all self reported HIV positive participants excluded) 
On PrEP 70 11.6 
Not on PrEP 416 69.2 
Never heard of PrEP 69 11.5 
Not Reported 46 7.7 
 
Procedure  
The current study was conducted as a collaboration between Queensland 
AIDS Council, Lives Lived Well and the University of Southern Queensland (USQ). 
USQ Human Research Ethics Committee granted approval for the study 
(H16REA116; Appendix A). The study involved the completion of a 15 to 20 minute 
survey which participants completed online (75.1%) or in paper form (24.9%), 
depending on where they were recruited. Participants were able to complete a paper 
form if they wanted to complete it at the time or were given a web address to 
complete at their leisure. The survey was hosted through Survey Monkey 
(https://www.surveymonkey.com/r/QChemSex). Surveys completed in paper format 
were manually enter into survey monkey and checked for fidelity by QuAC staff. 
The first page of the questionnaire on either the electronic or paper form was a 
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participant information form which included a description of the study, potential 
risks and benefits to the participant, the ethics approval number, information for 
contacting the researchers and request for participant consent. Participant consent 
was deemed provided by completion and submission of the questionnaire, and was 
stated explicitly to participants on participant information sheet (see Appendix B). 
Participants were not offered any incentives to participate in the study. There was no 
expected direct benefit to participants, other than to contribute to a greater 
understanding of the lives and experiences of MSM and to inform health promotion 
for this community. As outlined in the participant information sheet and ethical 
approval, no identifying data was collected from participants. 
Measures 
Target behaviours. The questionnaire asked participants about a number of 
specific target behaviours aligned with the project aims, including engagement in 
chemsex, which was defined as “chemsex…involves the use of drugs, to facilitate or 
enhance sexual activity, with or without other drugs.” Participants were also 
informed that they may know this behaviour as ‘party and play’. The other target 
behaviour was CAI with partners of unknown or serodiscordant HIV status. 
Participants were asked if they had engaged in this behaviour either sober and or 
whilst intoxicated (“drunk or high”). To operationalise this behaviour participants 
were provided with the definition “serodiscordant status means one partner is HIV 
positive and the other is HIV negative.”  
Questionnaire. Participants were asked a number of questions about their 
drug use and sexual health in addition to the Drinking Expectancies Questionnaire 
(DEQ-MSM; Mullens et al., 2011b) and the Stimulant Expectancies Questionnaire 
(SEQ-MSM; Mullens, 2011). Participants who endorsed the target behaviour of 
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chemsex were asked further questions about their experiences of chemsex and their 
drug use during the course of chemsex. Participants who did not endorse the target 
behaviour of chemsex were not asked further questions. In addition to demographic 
variables, participants were asked how they heard about the study, and how they 
would most like to access further information about sexual health and substance use. 
In addition to these questions, the survey considered of a section on general drug use 
and a number of questions on sexual health practices. 
Person-related variables. All wording of questions and response options 
were developed based on the format and phrasing of the GCPS (Lee et al., 2017) in 
addition to consultation with health promotion staff at QuAC.  
 Age. Participants’ age was collected at the beginning of the questionnaire. 
The age ranges were in 10 year brackets, with the exception of the first and last 
bracket which included 18-29 years and 80+ years. These brackets were coded in 
ascending order (1) = 18-29 years to (7) = 80+ years. 
 Gender. Participants’ self reported gender was also collected at the beginning 
of the questionnaire. Participants were given the options: “male”, “female”, “trans*” 
and “Other/ Decline to answer (please specify)”. Free text responses were later 
allocated to either (1) = male or (2) = trans*, depending on responses. As a result, 
trans participants may identify as ‘gender non-conforming’ or other variations.   
Sexual Orientation. Participants self reported sexuality was collected, 
participants were given the options ‘gay/homosexual’, ‘bisexual’, ‘heterosexual’ and 
‘other (please specify)’. Six participants specified their sexuality as ‘pansexual’ and 
these were given their own category, all other specified sexualities were defined as 
‘other’. Each category was coded (1) = gay/homosexual, (2) = bisexual, (3) = 
heterosexual, (4) = pansexual, (5) = queer and (6) = other. 
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Ethnicity. Participants were asked two separate questions about their 
ethnicity. Specifically about their Aboriginal or Torres Strait Islander status and their 
“ethnic background”. Australian indigenous status was coded, (1) = Aboriginal, (2) = 
Torres Strait Islander, (3) = Aboriginal and Torres Strait Islander or (4) = neither 
Aboriginal nor Torres Strait Islander. Ethnic background was coded as either, (1) = 
Anglo-Australian or (2) = other.    
Residence. Participants were asked where they were born, this was coded (1) 
= Australia, (2) = Overseas. Participants were also asked where they currently live. 
Post codes were collected as four digit numeric numbers. Participants were also 
asked if they lived in an urban, regional or rural area. This was coded as (1) = 
Urban/City, (2) = Regional and (3) = Rural or Remote.    
Drug and alcohol use. Drug use time frames. Participants were provided the 
following list of drugs and asked to indicate if they had used the drug in one of three 
time frames: “the last 0-3 months”, “the last 3-6 months”, and “the last 6-12 
months”, these were scored as a binary of either endorsing the time period (1) or not 
endorsing the time period (0). The list of drugs as is follows: Marijuana, Amyl 
(Amyl Nitrate), Ecstasy, Amphetamine (speed), Crystal Methamphetamine, 
Sildenafil (Viagra), Cocaine, Ketamine, GHB, Heroin, Steroids and Alcohol. This 
list was chosen based on the prevenance rates of these drugs as reported in The Gay 
Community Periodic Survey 2015 (Lee et al., 2016) and consistent with published 
research in this sector (Mullens et al., 2009). 
Drug use frequency. Participants were given an identical list of drugs as 
those listed above and asked to rate the frequency of use. From (7) = Everyday, (6) = 
2-3 times a week, (5) = once a week, (4) = once a month, (3) = once every 3 months, 
(2) = once every 6 months and (1) = once every 12 months.  
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Sexual health. HIV testing. Recency of last HIV tested was established by 
asking “When was your last HIV test?” participants were given seven options from 
(1) = one to four weeks ago through to (6) = more than four years ago and (7) = 
never tested.   
HIV status. Participants were given three options in relation to their HIV 
status: (1) = positive, (2) = negative and (3) = not sure. 
Viral load. Those participants who reported being HIV positive were further 
asked about their most recent viral load test. Responses were reported as (1) = 
undetectable, (2) = detectable. For use in the analysis UVL became a dummy 
variable with UVL = (1).  
PrEP. Participants who reported being HIV negative were asked if they were 
engaging in safer sex through the use of PrEP. Options for response were (1) = yes, 
(2) = no and, (3) = never heard of PrEP. This also became a dummy variable with 
participants taking PrEP coded as (1).  
ARV. Participants who reported either being on PrEP or being HIV positive 
and having an undetectable viral load were coded as (1) on this variable. All other 
participants who provided a response in either the PrEP question or the HIV status 
question were coded as (0). 
Other STIs. Participants were asked to indicate if they had acquired one or 
more STIs in the preceding 12 months. As per the investigated drugs, the list of STIs 
is based on prevalence rates from the 2015 Gay Community Periodic survey (Lee et 
al., 2016). The list is as follows: human papilloma virus (HPV), syphilis, herpes, 
hepatitis A, hepatitis B, hepatitis C, gonorrhoea, chlamydia and LGV 
(lymphogranuloma venereum). Participants were also given the option “I did not 
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contract any of the above in the last 12 months”. For use as an outcome variables this 
data was coded as (1) = reported at least one STI. 
Target behaviours – CAI and chemsex . CAI. Participants were asked if they had 
engaged in CAI in the preceding 12 months with partners of unknown or 
serodiscordant status and were provided the previously stated (see page 36) 
definition of “serodiscordant”. The options for response were: (1) = yes, (2) = no 
and, (3) = unsure. The unsure option was provided in this question and the following 
question in order to capture participants who may have engaged in the behavior but 
do not have a clear recollection of the experience due to intoxication or other factors.  
CAI: intoxicated. This question was identical to the previous question, but to 
add the words “whilst drunk of high”. The response options were also identical. To 
include this data in the analysis, the “unknown” responses were dropped and the 
remaining data was coded as, yes = (1), no = (0). 
Chemsex. As previously stated, the operationalized definition of chemsex 
was given to participants, followed by a question asking if they had engaged in 
chemsex in the last 12 months. Options for response we (1) = yes and (0) = no. Only 
participants who responded in the affirmative were asked the following questions 
about their activities and drug use during chemsex. 
Frequency of chemsex. Participants were given five options as to how often 
they had chemsex: (1) = daily, (2) = weekly, (3) = fortnightly, (4) = monthly and, (5) 
= yearly.  
Duration of chemsex sessions. Participants were asked about the duration of 
their chemsex sessions. Time periods of four hour blocks were presented from (1) = 
one to four hours, through to (12) = 45-48 hours. This data was extremely skewed. 
After attempting to use the full set of data in analysis, the cells at one end were far 
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too small to give meaningful results. The data was re-coded into two separate 
dummy variables for, five to eight house and nine plus hours.  
Sexual positioning during chemsex. Participants were asked two questions 
with respect to sexual positioning during chemsex. These questions were used as a 
further indication of sexual health risk, as the receptive partner is more susceptible to 
HIV transmission biologically (Varghese, Maher, Peterman, Branson, & Stekettee, 
2002). Participants were asked if they had engaged in receptive CAI and were 
provided with the following response options, (1) = yes, (2) = no and, (3) = not sure. 
Participants were asked the same question in respect to insertive CAI and were 
provided with the same response options.  
Substances used during chemsex. Participants were presented with the same 
list of drugs that had been previously presented, with one addition, mephedrone 
(‘meow meow’) and were asked if they had used any of the drugs during chemsex, 
with (1) = yes and (2) = no response options. They were also given an “other” option 
to enter any other drugs they may have used.  Participants were also asked about the 
frequency of drugs used during chemsex. The same list of drugs was presented with 
response options: (5) = always, (4) = very often, (3) = often, (2) = sometimes and (1) 
= never. Participants were also given an “other” option in this question. 
 
Results 
Preliminary Analyses 
Preliminary analyses showed that none of the test variables fulfilled the 
assumption of normality due to the categorical nature of the data, therefore non-
parametric statistics were used for most analyses. Chi-Square tests were used for some 
categorical comparisons, this test compares the expected cell sizes with actual cell 
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sizes to give a likelihood that the difference in cell sizes occurred at random, or due to 
an effect. Mann-Whitney U is a test that compares median values. This test was used 
for a number of comparisons comparing ordinal data. Logistic regression was used to 
test a number of the study hypotheses. This test outlines the contribution to the model 
that each variable made. The primary assumption of logistic regression are linearity of 
logit. As per Field (2009) each model was tested for linearity of the logit and all results 
of these analysis were non-significant. This indicted that the assumption of linearity 
of the logit was not violated.   
  The total sample included 663 cases. A further subset of the data formed the 
basis for much of the statistical testing. The key grouping variable of interest was 
whether or not participants had engaged in chemsex, 211 participants reported 
having engaged in chemsex in the last 12 months.  
Missing Data Implications 
Chi-square analysis was run to explore the differences between those who did 
answer the key questions and those who did not. Those who did not respond to the 
question “have you engaged in chemsex in the last 12 months?” were more likely to 
be bisexual (χ2 = 16.50, p <.01, n = 661), but showed no significant difference on age 
(χ2 = 11.98, p =.06, n = 663), gender (χ2 = 1.06, p =.59, n = 663), place of birth (χ2 = 
1.75, p =.19, n = 651) or Aboriginal or Torres Strait Islander status (χ2 = 2.46, p 
= .48, n = 657) compared to those who did provide a response to the question. Where 
the n values fall below 663, respondents did not provide a value for that demographic 
variable. Those who did not respond to the question “when was your last HIV test?” 
were more likely to identify as transgender (χ2 = 8.66, p =.013, n = 661), bisexual (χ2 
= 31.85, p <.01, n = 661), and have been born overseas (χ2 = 17.85, p <.01, n = 651). 
They did not differ on age (χ2 = 2.53, p =.87, n = 663), place of residence (χ2 = .41, p 
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=.82, n = 639) or Aboriginal or Torres Strait Islander status (χ2 = 1.58, p =.66, n = 
657). People not reporting their HIV status were more likely to be born overseas (χ2 
= 5.3, p = .02, n = 651), more likely to identify as bisexual (χ2 = 36.96, p <.01, n = 
661) and more likely to identify as transgender (χ2 = 11.52, p <.01, n = 663). They 
did not differ on other demographic variables. While the amount of missing data was 
small, the results must be interpreted in light of the fact that it may be 
underrepresenting transgender people, people not identifying as gay or homosexual 
and members of the community who are born overseas.  
All hypotheses that use the term “CAI” refer to the variable that asked 
participants “Have you had condom-less anal sex in the past 12 months with any 
partners of unknown or serodiscordant status whilst drunk or high?” 
Differences Between Online Verses Paper Form 
The differences between those who completed the survey online verses those 
who completed it in paper form were explored. Participants who completed the 
survey on paper were primarily recruited and had their responses recorded at SOPV’s 
which gives insight into the behaviours of this particular group. Participants 
completing the paper form were more likely to have had a recent HIV test. The 
differences between those who completed the survey online verses those who 
completed it in paper form were explored. Participants who completed the survey in 
paper were recruited and had their responses recorded at SOPV’s. Participants 
completing the paper form were more likely to have had a recent HIV test (χ2 = 
28.55, p < .01, n = 635), more likely to be older (χ2 = 43.75, p <.01, n = 663), more 
likely to be Aboriginal or Torres Strait Islander, (χ2 = 12.68, p < .01, n = 657), more 
likely to be born overseas (χ2 = 4.40, p = .04, n = 651) and more likely to be on PrEP, 
(χ2 = 18.83, p <.01, n = 572). There were no difference on sexuality (χ2 = 6.03, p 
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= .30, n = 661) or gender (χ2 = .10, p = .61, n = 663) and they were not more likely to 
have engaged in chemsex in the last 12 months (χ2 = 2, p = .10, n = 582). 
Descriptive Analysis of the Data (Hypothesis 1) 
The first aim of this study was to report on current rates of drug use and 
sexual activity among people who report engaging in chemsex. It was hypothesised 
that people who did engage in chemsex would be significantly different from those 
who did not engage in chemsex on key demographic variables, including: sexuality, 
gender, age, Aboriginal or Torres Strait Islander status, place of birth, place of 
residence, ethnic background, HIV status, STI rates, reports of CAI, recentness of 
HIV testing, and PrEP use. 
Presented in Table 3 are the descriptive frequencies, totals, means and 
medians of drug use within the overall sample. Lower means indicate lower levels of 
substance use. Based on the median and mean scores across all time periods the three 
most commonly use illicit substances were: alcohol, marijuana and amyl nitrate. The 
substance with lowest reported usage was heroin. The percentage of participants who 
did not answer the question are included, this allows for easier comparison across 
substance type. While it may be possible that participants did not want to report on 
their drug use, given the anonymity of the study it is more likely that participants 
reported as missing had not used the substance in the last 12 months. Table 4 
provides descriptive frequencies on key sexual health variables within the whole 
sample. Table 5 provides descriptive frequencies on key sexual health variables 
within the chemsex subset of the data. 
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Table 3 
General Drug Use Within the Overall Sample  
 Total  Median/ 
Mean 
Everyday 2-3 times per 
week 
Once per 
week 
Once a 
month 
Once every 3 
months 
Once every 6 
months  
Once every 
12 months  
Missing 
Alcohol 81.1% 
(538) 
5/ 5.02 10.7% 
(71) 
24% (159) 21.3% (141) 14% (93) 6% (40) 3% (20) 2.1% (14) 18.9% (125) 
Marijuana 34.1% 
(226) 
4/ 4.11 5.9% (39) 5.7% (38) 3% (20) 5.3% (35) 5.1% (34) 3.9% (26) 5.1% (34) 65.9% (437) 
Amyl 43.6% 
(289) 
4/4.09 0.9% (6) 10.7% (71) 8% (53) 8.6% (57) 7.1% (47) 3.8% (25) 4.5% (30) 56.4% (374) 
Crystal 
Methamphetamine 
17.5% 
(116) 
4/ 3.90 1.4% (9) 2.1% (14) 4.2% (28) 3% (20) 2.4% (16) 1.2% (8) 3.2% (21) 82.5% (547) 
Sildenafil (Viagra) 23.8% 
(158) 
4/ 3.80 0.3% (2) 2.4% (16) 6.2% (41) 6.3% (42) 3.3% (22) 2.4% (16) 2.9% (19) 76.2% (505) 
Steroids 2.4% 
(16) 
3/ 3.13 0.2% (1) 0% (0) 0.5% (3) 0.5% (3) 0.5% (3) 0.2% (1) 0.8% (5) 97.6% (647) 
Heroin 1.8% 
(12) 
3/ 3.08 0.2% (1) 0.2% (1) 0.2% (1) 0.2% (1) 0.5% (3) 0.2% (1) 0.6% (4) 98.2% (651 
Amphetamine 
(‘Speed’) 
12.9% 
(86) 
3/ 3.08 0.9% (6) 1.8% (12) 2.1% (14) 2.1% (14) 1.2% (8) 1.5% (10) 3.3% (22) 89% (590) 
GHB 7.5% 
(50) 
3/ 2.86 0% (0) 0.6% (4) 0.9% (6) 1.4% (9) 1.1% (7) 1.2% (8) 2.4% (16) 92.5% (613) 
Ecstasy 21.7% 
(144) 
2/ 2.069 0% (0) 0.8% (5) 1.5% (10) 3.6% (24) 3.9% (26) 5% (33) 6.9% (46) 78.3% (519) 
Ketamine 4.4% 
(29) 
2/ 2.07 0% (0) 0% (0) 0% (0) 0.6% (4) 1.1% (7) 0.8% (5) 2% (13) 95.6% (634) 
Cocaine 10.1% 
(66) 
1/ 2.02 0.2% (1) 0.5% (3) 0.2% (1) 0.6% (4) 1.4% (9) 1.8% (12) 5.4% (36) 90% (597) 
N = 663 
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Table 4 
Sexual Health Data – Whole Sample 
 n % Missing 
STI acquisition last 12 months   4.4% 
(29) 
Did not acquire an STI  514 77.5%  
Acquired an STI 120 18.1%  
Acquired more than one an STI  37 5.6%  
    
CAI U/S HIV S* in the last 12 months   14.9% 
(99) 
Yes 182 27.5%  
No 330 49.8%  
Unsure 52 7.8%  
CAI U/S HIV S* while ‘drunk or high’   14.6% 
(97) 
Yes 145 21.9%  
No 398 60%  
Unsure 23 3.5%  
Low Risk (PrEP or UVL) 125 18.9% - 
High Risk (No ARVs and CAI) 103 15.5% 13.6% 
Engaged in chemsex   12.2% 
(81) 
Yes 211 31.8%  
No 371 56%  
Note. *= CAI with partners of unknown or serodiscordant HIV status in past 12 months  
N = 663 
 
 
Table 5 
Sexual Health Data – Chemsex Subset 
 n % Missing 
Frequency of having chemsex.    2.4% (5) 
Daily 1 0.5%  
Weekly 28 13.3%  
Fortnightly 30 14.2%  
Monthly 72 34.1%  
Yearly 75 35.5%  
Receptive CAI during chemsex   0.5% (1) 
Yes 126 59.7%  
No 77 36.5%  
Unsure 7 3.3%  
Insertive CAI during chemsex   0.5% (1) 
Yes 119 56.4%  
No 87 41.2%  
Unsure 4 1.9%  
N = 211 
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Demographic and sexual health differences: Chemsex compared to no chemsex. 
Demographic differences were assessed using chi-square. There were no 
significant differences between those who did report engaging in chemsex in the last 
twelve months and those who reported not doing so on these demographic variables: 
sexuality (χ2 = 10.11, p = .07, n = 582), gender (χ2 = 0.57, p =.75, n = 582), age (χ2 = 
24.02, p <.01, n = 582), place of birth (χ2 = 0.06, p =.80 , n = 582) or place of 
residence (χ2 = 1.03, p =.60, n = 582).  
Sexual Health and Demographic Differences 
Chemsex compared to no chemsex. Those who engaged in chemsex were 
more likely to be HIV positive (χ2 = 24.71, p <.01, n = 582) and they were more 
likely to have contracted an STI in the last 12 months (χ2 = 12.38, p <.01, n = 580). 
Those who engage in chemsex are also more likely to be on ARVs (χ2 = 38.06, p = 
<.01, n = 582). Participants who reported engaging in chemsex also reported having 
more CAI with serodiscordent or unknown partners both overall (χ2 = 38.74, p <.01, 
n = 582) and in the context of being ‘drunk or high’ for the whole sample (χ2 = 
115.62, p <.01, n = 582), just for people with UVL (χ2 = 9.44, p <.01, n = 49), just 
for people on PrEP (χ2 = 13.09, p <.01, n = 63) and for people not on ARVs (χ2 = 
69.74, p <.01, n = 430).      
Those who are not HIV positive (reported as negative or unknown) who do 
engage in chemsex are more likely to have had a more recent HIV test than those 
who have not engaged in chemsex in the last 12 months (U = 25472.500, p = .02, n = 
520). Participants who are either HIV negative or unknown and have had chemsex in 
the last 12 months, are also more likely to be on PrEP than people who have not had 
chemsex in the last 12 months (χ2= 17.54, p<.001, n = 503). 
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Of those who are HIV positive, there is no significant differences on viral 
load between those who do engage in chemsex and those who don’t (χ2 = 0.22, p 
= .47, n = 60). 
Participants reported on how often they used a number of drugs, ranging from 
‘once every 12 months’ to ‘everyday’. Using Mann-Whitney U to compare 
participants who did and did not engage in chemsex, with the exception of alcohol 
(U = 38314, p =.67 , n = 582), those who did engage in chemsex were significantly 
more likely to use all listed drugs, as follows: marijuana (U = 24404.50,  p <.01 , n = 
582), Amly Nitraite (U = 21626.50, p <.01, n = 582), Ecstasy (U = 26665.50,  p<.01, 
n = 582), Speed (U = 31519.50, p<.01, n = 582), Crystal Methamphetamine 
(U=20246.50, p <.01, n = 582), Sildenafil (U = 25921, p <.001, n = 582), Cocaine 
(U= 32534, p <.01, n = 582), Ketamine (U=34401, p <.01, n = 582), GHB 
(U=30964, p <.001, n = 582), Heroin (U=37351, p = .003, n = 582), steroids 
(U=37579.50, p =.02, n = 582).  
 Demographics of chemsex participants. Of those who engaged in chemsex 
78.7% (n = 166) identified as homosexual or gay, 18% (n = 38) identified as bisexual 
and 3.4% (n = 7) identified as another sexuality. There was 50 (23.7%) 18-29 year 
olds, 58 (27.5%) 30-39 year olds, 61 (28.9%) 40-49 year olds, 34 (16.1%) 50-59 year 
olds and 8 (3.8%) participants over 60 years old. Of those who engaged in chemsex 
49.3% (n = 104), reported having CAI with partners of unknown or serodiscordent 
status while drunk or high, a further 6.6% (n = 14) were unsure if they had done so. 
Most participants reported having chemsex yearly (36.4%, n = 75) however 35% (n 
= 72) reported having chemsex monthly, 14.2% (n = 30) reported having chemsex 
fortnightly and 13.3% (n = 28) reported having chemsex weekly. The majority 
(42.7%, n = 90) of participants reported their chemsex sessions lasted for 1-4 hours 
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and the median session length was 5-9 hours. Of those who engaged in chemsex 
26.6% (n = 56) reported having been diagnosed with an STI in the last 12 months. 
The following table details the drug use during chemsex of the 211 participants who 
reported they engaged in chemsex in the last 12 months.  
Table 6 
Drugs used during chemsex 
 Always 
% (n) 
Very often Often Sometimes Never Missing 
Amyl 
Nitraite 
21.8(46) 14.7% (31) 11.4% (24) 24.2% (51) 11.4% (24) 16.6% (35) 
Crystal 
Methamphet
amine 
16.6% (35) 11.4% (24) 5.2% (11) 14.7% (31) 25.6% (54) 26.5% (56) 
Marijuana 10% (21) 10.9% (23) 7.6% (16) 19% (40) 25.6%(54) 27% (57) 
Sildenafil 8.5% (18) 13.3% (28) 10% (21) 17.5% (37) 24.2% (51) 26.5% (56) 
Alcohol 8.5% (18) 8.5% (18) 10.9% (23) 32.2% (68) 22.3% (47) 17.5% (37) 
Ecstasy 1.9% (4) 3.8% (8) 3.3% (7) 27.5% (58) 34.1% (72) 29.4% (62) 
Amphetamin
e 
1.9% (4) 3.3% (7) 3.8% (8) 16.6% (35) 39.3% (83) 35.1% (74) 
GHB 1.4% (3) 2.8% (6) 4.7% (10) 10.4% (22) 42.7% (90) 37.9% (80) 
Cocaine 0% (0) 0.9% (2) 0.5% (1) 7.6% (16) 50.2% (106) 40.8% (86) 
Steroids 0% (0) 0.9% (2) 0% (0) 0.9% (2) 55.9% (118) 42.2% (89) 
Heroin 0% (0) 0.5% (1) 0.5% (1) 0.5% (1) 57.3% (121) 41.2% (87) 
Mephedrone 0% (0) 0% (0) 0.5% (1) 2.8% (6) 55.5% (117) 41.2% (87) 
Note. n = for each cell is in brackets 
Correlations 
Presented in Table 7 is the correlations for each of the variables used in the 
following analyses. Numbers on the horizontal axis correspond to the equivalent 
numbers and variables on the vertical axis.  
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Table 7 
Bivariate correlations of variables including alpha levels.   
Variable 1. 2. 3. 4. 5.  6. 7.  8. 9. 
1. PrEP 1         
2. UVL -.11** 1        
3. STIs .27** .04 1       
4. Chemsex .15** .20** .15** 1      
5. CAI .22** .17** .28** .46** 1     
6. Lenght .10 .27** .04 - .32** 1    
7. GHB .17 .18* .10 - .24** .36** 1   
8. Mephedrone .13 -.10 .02 - -.02 .08 .4 1  
9. CM .06 .30** .04 - .32** .58** .48** .04 1 
* p <.05, **<.01; 
Note. CM = Crystal Methamphetamine; Length = Length of sexual session. 
 
Data Analysis of the Relationship Between CAI and Various Chemsex Drugs 
(Hypothosis 2) 
It was predicted that one of the key chemsex drugs (cystral 
methamphetamine, GHB or mephedrone) will have more of an influence on CAI 
than the others (Hypothesis 2). As such, this analysis only contains data for people 
who did report engaging in chemsex. The relationships between these variables were best 
tested using a logistic regression model. The constant was a binary response of, “yes, 
I engaged in CAI in the last 12 months” or “no, I did not engage in CAI in the last 12 
months”. Yes was coded as 1, while no was coded as 0. Participants were asked 
“how often do you use the following drugs during chemsex?”, and they were able to 
select multiple drugs and time periods, they may or may not have used each of the 
drugs together.   
A logistic regression analysis was conducted to predict CAI. Reported 
engagement in CAI was the outcome variable, while the use of crystal 
methamphetamine, GHB and mephedrone use during chemsex were the predictors. 
The model before predictors were entered (Step 0, constant only model) is presented 
in Table 8. A test of the full model against a constant only model was statistically 
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significant, indicating that the predictors of chemsex and use of crystal 
methamphetamine, GHB and mephedrone during chemsex are significant predictors 
of CAI (χ2 = 13.89, p < .01 with df = 3). A Nagelkerke’s R2 of .16 (-2 Log likelihood 
= 135.24; Cox & Snell R Square = .12) indicated a moderately strong relationship 
between prediction and outcome. Prediction success overall was 64.8% (76% for not 
having engaged in CAI and 55.2% for having engaged in CAI). The Wald criterion 
of 5.04 demonstrated that crystal methamphetamine usage made a significant 
contribution to the model (p <.01). However, no other predictors were significant. 
This finding supported Hypothesis 2.  
Table 8 
Logistic Regression, Exploration of the relationship between CAI and crystal 
Methamphetamine, GHB and Mephedrone 
  B SE Wald 
(χ2) 
OR CI 
lower 
 CI 
upper 
Step 
0 
Constant .15 .19 .59 1.16   
Step 
1 
Crystal 
Methamphetamine 
.34* .15 5.0 1.4 1.04 1.87 
 GHB .39 .31 1.61 1.48 .81 2.69 
 Mephedrone -.34 .75 .21 .71 .16 3.10 
 Constant -.86 .88 .95 .43 .16 3.10 
*p  <.05, **p<.01 
Note: n = 108; 
 
To judge the odds change for crystal methamphetamine, a follow up logistic 
regression was run, using crystal methamphetamine as a single predicator. The 
results are shown in Table 9, they show that a significant Wald (13.51; p < .01) was 
found. The odds ratio of 1.54 indicates that when taking crystal methamphetamine 
during chemsex, participants were one and a half times more likely to have CAI than 
when not taking crystal methamphetamine. The regression was highly significant 
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with a p <.01 and an effect size of .13 (Nagelkerke R square; -2 Log likelihood = 
179.60; Cox & Snell R square = .10). Chi-square for the model was 14.97.    
Table 9 
Logistic Regression, Exploration of the relationship between CAI and crystal 
Methamphetamine only 
 B SE Wald 
(χ2) 
OR OR 
CI 
lower 
OR 
CI 
upper 
Crystal 
Methamphetamine 
.43** .12 13.51 1.54 1.23 1.95 
Constant -.85 .34 6.32 .427   
 **p <.01 
Note: n = 142;  
The analysis was also conducted on the group of participants who were not 
on PrEP, did not have an undetectable viral load and had not otherwise reported use 
of any ARVs. This model showed a significant Wald criterion (8.30; p<.01). It 
showed that participants in this group were 1.55 times more likely to engage in CAI 
during chemsex if they were using crystal methamphetamine. Results are shown 
below in Table 11. Effect sizes were moderate (-2 Log likelihood = 112.12; Cox & 
Snell R Square = .10; Nagelkerke R Square = .13). Chi-square for the model was 
9.14 (df =1). Due to the small number of cases these results should also be 
interpreted with caution.  
Table 11 
Logistic Regression, Exploration of the relationship between CAI and crystal 
Methamphetamine only 
 B Standard 
Error 
Wald 
(χ2) 
OR CI for 
ExP 
(B) 
lower 
CI 
ExP 
(B)  
upper 
Crystal 
Methamphetamine 
.44** .15 8.30 1.55 1.15 2.08 
Constant -1.17** .41 8.34 .31   
*p<.05, **p<.01 
Note: n = 88 
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If sufficient data were available, a further analysis would have been 
conducted looking at the relationship between CAI and crystal methamphetamine use 
for PLWH who had a detectable viral load, however there were only eight 
participants who had a detectable viral load, meaning that a meaning analysis would 
not be possible.  
Length of Chemsex Session and its Effect on CAI (Hypothosis 3) 
In order to test the hypothesis that longer chemsex sessions will increase the 
likelihood of participants engaging in CAI (Hypothosis 3), a logistic regression was 
run. In order to use the three levels of the variable, one to four hours, five to nine 
hours and nine or more hours, two dummy coded variable were created and entered 
into the model. The constant in addition to the five to nine hours dummy and the nine 
or more hours dummy were entered into the model. The model before predictors 
were entered (Step 0, constant only model) is presented in Table 12. A test of the full 
model against a constant only model was statistically significant, indicating that with 
each increasing time period, likelihood of CAI increases. A Nagelkerke’s R2 of .13 (-
2 Log likelihood = 241.19; Cox & Snell R Square = .10) indicated a moderately 
strong relationship between prediction and outcome. Prediction success overall was 
65.1%, (62.5% for not having engaged in CAI and 67.3% for having engaged in 
CAI). The Wald criterion for ‘more than nine hours’ (17.92) makes a significant 
contribution to the model, as do the Wald criterion associated with ‘five to nine 
hours’ (4.38) and the constant (5.38). Sessions of more than nine hours were 
significant at p<.01. The constant, which account for sessions of less than five hours, 
was significant at p = .02 and sessions of five to eight hours were significant at p 
= .04.  Chi-square for the model was 19.93 (df = 2; p<.01). These findings supported 
the hypothesis that increasing chemsex session length would increase CAI.  
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Table 12 
Logistic Regression, Exploration of the relationship between increasing time 
intervals and their effect on CAI 
  B Standard 
Error 
Wald 
(χ2) 
OR OR CI 
lower 
OR CI 
upper 
Step 
0 
Constant .14 .15 .89 1.15   
Step 
1 
More than 
nine hours 
1.55** .37 17.92 4.69 2.29 9.59 
 Five to nine 
hours 
.81* .39 4.38 2.26 1.05 4.83 
 Constant -.51* .22 5.38 .60   
*p  <.05, **p<.01;  
Note. n = 189 
 
Condomless Anal Intercourse as an Outcome Variable (Hypothosis 4) 
Due to the protective power of ARVs, it was expected that people engaging 
in chemsex were more likely to be using ARVs and this would lead to more CAI 
(Hypothesis 4). In order to test this hypothesis, two logistic models was fitted 
looking at how CAI varied by UVL, PrEP, chemsex and an interaction term for each 
test. Each of the main effects were significant however the interaction terms were 
not. Then a model was fit looking at main effects for each of UVL, On PrEP and 
chemsex, all of which were significant predictors of CAI, with a moderate effect size 
(; -2 Log likelihood = 497.42; Cox & Snell R Square = .22; Nagelkerke R Square 
= .32). Chi-square for the model was 132.15 (p<.01; df = 3). 
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Table 13 
Logistic Regression, exploring to contributions to the outcome of CAI 
  B Standard 
Error 
Wald 
(χ2) 
OR OR CI 
lower 
OR 
CI 
upper 
Step 
0 
Constant -1.01** .10 107.74 .37   
Step 
1 
UVL .96** .35 7.73 2.62 1.33 5.17 
 On PrEP 1.30** .31 16.98 3.65 1.97 6.76 
 Chemsex 2.03** .23 80.00 7.58 4.86 11.82 
 Constant -2.24** .18 154.37 .11   
*p <.05, **p<.01 
Note: n = 542 
 
Sexually Transmitted Infections as an Outcome (Hypothosis 5) 
It was predicted that chemsex would increase the risk of acquiring non HIV 
STIs due to the use of ARVs (undetectable or on PrEP) in conjunction with CAI 
(Hypothesis 5). In order to test this hypothesis, a logistic model was fitted looking at 
how STI is varied by PrEP and UVL and CAI together, including an interaction term. 
The main effects were found to be significant (p<.01; p<.01), with the exception of 
UVL (p =.89), but the interactions were not found to be significant (p = .82).  
Then a model was fit, looking at how STI varied by on PrEP, UVL and 
chemsex together including interaction terms. Being on PrEP was a significant 
predictor (p <.01) and chemsex was not a significant predictor (p = .06). The 
interaction terms were not significant (p = .33).  
Then a model was fit looking at main effects for each of CAI, chemsex and 
UVL and on PrEP and CAI. On PrEP (p <.01) and CAI (p <.01) were found to be 
significant predictors but chemsex (p = .81) and UVL (p =.35) were not. CAI and 
chemsex are highly correlated, as shown in Table 7, with a correlation of .46. The 
analysis with four main effects, two of which are significant are shown in Table 14. 
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Effect size for the model was moderate (-2 Log likelihood =454.11 ; Cox & Snell R 
Square = .10; Nagelkerke R Square = .17) with a chi-square of 57.42 (df =4). 
Table 14 
Logistic regression showing PrEP and CAI making a contribution to the 
outcome of having acquired an STI. 
  B Standard 
Error 
Wald 
(χ2) 
OR OR CI 
lower 
OR 
CI 
upper 
Step 
0 
Constant -
1.51** 
.11 182.01 .22   
Step 
1 
Undetectable viral 
load 
.36 .38 .88 1.43 .68 3.04 
 On PrEP 1.37** .31 19.95 3.95 2.16 7.21 
 CAI 1.18** .28 18.02 3.24 1.88 5.58 
 Chemsex .07 .28 .06 1.07 .62 1.84 
 Constant -2.22 .18 152.16 .11   
*p  <.05, **p<.01 
Note: n = 540 
 
 
Discussion 
The current study has provided a detailed investigation of key behaviours and 
demographics of MSM who are engaged in sexual activity and drug use (chemsex) 
within an Australian sample. Australian research on chemsex has been limited and 
mostly qualitative (Lea et al., 2016; Race, 2015). The current study included at a 
sample of over 650 participants who reported on their engagement in sexual activity 
and drug use, shedding needed light on the related and harmful behaviours associated 
with chemsex. First a summary and explanation of the results found in this study are 
provided, followed by how the study is consistent with and aligns with previous 
research. Clinical implications are then discussed in detail, given that one of the key 
aims of the project was to provide useful evidence-based data for QuAC to guide 
future health promotion and HIV prevention. Strengths and limitations are provided 
and directions for future research as discussed.   
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Summary and Interpretation of Findings 
Before discussing the interpretation of the results, it is worth noting the 
underrepresentation of a number of groups within the sample, as it is pertinent for the 
implications of the study. The missing data in this study indicated that a number of 
groups were underrepresented. It is also likely these groups may be underrepresented 
in other research of this kind (Fish, 2008). People born overseas and MSM who do 
not identify as ‘gay or homosexual’, including transgender people and bisexuals, 
were distinct subsets of people who declined to respond to a number of key questions 
within the survey. This lack of engagement indicates the possibility that these 
populations are further stigmatised within the community or do not feel that the 
research applies to them. There is evidence that bisexuals (Schrimshaw, Siegel, 
Downing, & Parsons, 2013), transgender people (Fabbre, 2017; Poteat, German, & 
Kerrigan, 2013) and people born overseas (Herrmann et al., 2012), have different 
experiences as a result of their identities and often face stigma or other barriers both 
in everyday living but in particular to accessing appropriate health and preventative 
care.  
To outline the initial, drug use statistics; this study’s finding, that the most 
commonly used substances are alcohol, amyl nitrate and marijuana, are consistent 
with the most recent GCPS (Lee et al., 2017). The key differences between this study 
and the GCPS being that the GCPS asked about the previous 6 months while the 
current study asked by the prior 12 months. The GCPS also uses different 
recruitment strategies. The current study also specifically recruited drug users which 
we would expect to increase the participants reporting drug use. The GCPS reported 
approximately 30% (for each drug) of their sample used marijuana and amyl nitrate 
in the previous six months. The current study found approximately the same for 
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marijuana but approximately 43% of the sample using amyl nitrate. It is likely that 
the subset of the gay community that the current study sampled, is using more amyl 
nitrate than the community as a whole. Also of note is the high prevalence of alcohol 
use; though notable, not necessary excessive. The GCPS asked about harmful levels 
of drinking while the current study reports more general alcohol use meaning they 
are not comparable. However the ABS reported that statistics collected in 2015 
suggest that approximately 85% of Australian men has reported consuming alcohol 
in the previous 12 months (Australian Bureau of Statistics, 2017), which is more than 
the 81% found in the present study.  The ABS also reported that Australian men (in 
2015) reported, on average, two or more standard drinks most days (Australian 
Bureau of Statistics, 2017). The present study found only 10% of the sample 
reporting drinking alcohol every day and 24% drinking alcohol ‘2-3 times per week’. 
These results would appear to indicate that the MSM in this sample are drinking less 
alcohol overall than the average for Australian men. 
Heroin was the drug with the lowest level of reported use (1.8% of the total 
sample) which was consistent with the 2016 GCPS (Lee et al., 2017). Assumedly this 
prevalence rate is due to a lack of access to the drug in Australia (Horyniak et al., 
2015), in addition to the much greater accessibility to drugs such as crystal 
methamphetamine (Usher, Clough, Woods, & Robertson, 2015). High levels of 
marijuana and amyl nitrate use are also noteworthy and cause for concern. The 
desired and perceived effects of amyl nitrate (Mullens, Young, Dunne, & Norton, 
2011a) and marijuana (Mullens, Young, Dunne, & Norton, 2010) have been 
previously detailed. For both of these drugs, MSM reported increased sexual 
pleasure in a number of ways and noted that decision making was impaired with the 
use of both these drugs. The prevalence of these two drugs within the MSM 
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community means their use is normalised and, at least for the people using them, the 
perceived benefits are substantial (Mullens et al., 2009).   
One of the main aims of the present study was to identify some of the 
differences between MSM who reported engaging in chemsex verses those who 
reported not engaging in chemsex. The fact that there were not significant 
differences in demographic factors between those who did and did not engage in 
chemsex, suggest that there are no fixed characteristics that the present study has 
identified, that have an impact on chemsex behaviour. All of the differences between 
the two groups relate to behaviour and HIV status and testing behaviour. This has 
implications for behaviour change, knowing that some of the factors involved in high 
risk behaviours are likely to be changeable. 
In exploring the differences between those who reported engagement in 
chemsex verses those who did not engage in chemsex, there were significant 
differences been the two groups on a number of sexual health factors. People 
engaging in chemsex were more likely to be HIV positive. While causation cannot be 
established, the majority of the chemsex literature (Hegazi et al., 2017; Schmidt et 
al., 2016; Stuart, Nwokolo, McOwan, Bracchi, & Boffito, 2015) reports high 
numbers of HIV positive men engaging in the behaviour. The most likely 
explanation is that chemsex facilitates many of the risk factors for HIV acquisition in 
addition to the chemsex population having high rates of HIV, makes acquiring the 
virus much more likely. Further differences between those who did and did not 
engage in chemsex, people engaging in chemsex were more likely to have engaged 
in CAI in the last 12 months. This was true across PLWH who had an UVL, 
participants on PrEP and participants not on ARVs; and had a large effect size. This 
suggests that this is a key feature of chemsex regardless of how high or low the risk 
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of doing so may be. People having chemsex were also more likely to have acquired 
an STI in the last 12 months. STI outcomes was the most key outcome in this study 
and will be discussed further. Chemsex participants also had higher rates of overall 
drug use. However, chemsex participants were also more likely to have had a recent 
HIV test and more likely to be using PrEP. For HIV positive participants, there was 
no difference between detectable and undetectable viral load but the sample of 
people with a detectable viral load was so small that if an effect existed, a larger 
sample would be required in order to identify it. So overall, people engaging in 
chemsex are far more likely to have been exposed to sexual health and drug use risks 
however they are also engaging in high levels of harm minimisation strategies. These 
results are consistent with much of the qualitative data explored in other studies 
(Bourne et al., 2014; Knoops et al., 2015). Explanations provided for limited condom 
use in previous research such as reduced sensation or inconvenience may be 
applicable (Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2015). Given that 
frequent testing and the use of ARVs do not have an impact of the enjoyment and 
gains received from chemsex in the moment, it would appear that men are making 
informed and rational choices based on accurate information about health risks. That 
is, they are aware of the risks they are exposing themselves to, are making the choice 
to continue that engagement, but using harm reduction practices such as regular 
testing and the use of ARVs. It will be important to harness this feature of the 
behaviour for best application of harm reduction strategies.  
After examining the general patterns within a sample, an analysis was 
conducted to consider how key chemsex drugs were effecting reports of CAI. It was 
found that the primary drug of interest was crystal methamphetamine with no 
significant effects from GHB or mephedrone. This shows that during chemsex, 
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crystal methamphetamine is the key drug associated with greater reports of CAI. As 
discussed in previous literature (Bourne, Reid, Hickson, Torres-Rueda, & 
Weatherburn, 2015; Mullens et al., 2009) disinhibition is one of the desired 
outcomes of substance use during sexual activity and the guilt or fear often 
associated with CAI may dissipate as a result of crystal methamphetamine. The fact 
that neither GHB or mephedrone contributed to CAI is likely an artifact of 
accessibility and the fact that these drugs are much less common in Australia then 
crystal methamphetamine (Degenhardt & Dunn, 2008; Degenhardt et al., 2017; Ness 
& Payne, 2011).    
Results from Hypothesis 3, exploring the relationships between CAI and 
length of chemsex session showed that, increase in length of chemsex session, 
increased the likelihood of engaging in CAI. While the majority of participants in the 
current study were not having chesmex sessions for more than 9 hours, there were a 
few who reported sessions of up to 48 hours. Bourne et al. (2014) reported MSM 
having chsemsex sessions of up to three or four days long. In the present study the 
focus was on CAI, however, there is also concern around how extended sessions may 
interfere with medication schedules for people on ARVs. Missing one or two doses 
of either PrEP or HIV treatment medications has the potential to result in a detectable 
(and therefore transmittable) viral load (Genberg et al., 2012) or sero-conversion in 
someone who was previously HIV negative (McCormack et al., 2016). While this 
risk is relatively small, it is an important consideration if ARVs are being using as a 
risk reduction strategy for participants. In addition to these risks, longer sexual 
sessions have significant physical health risks relating to tissue damage of sexual 
organs, which in turn increases the risks of HIV and STI transmission (Urbanus et 
al., 2009). As will be further detailed, CAI was shown to be a significant predictor of 
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STIs, so long sessions have both primary harms as well as secondary harms. Many of 
which may be reduced by engaging in shorter sessions. While MSM may be aware 
that longer sessions with substantial drug use have physical harms like tissue 
damage, more time needed to recover and fatigue, they may not be aware that longer 
sessions have an impact on their likelihood of engaging in CAI. These results suggest 
that while health promotion and education have been highly effective in some areas 
of sexual health for MSM, further and more specific messages may be needed. 
Education around the positives of having shorter sessions and use of lubricants may 
be beneficial. Additionally, targeting the messages around the efficacy of HIV 
prevention with PrEP and UVL to this population specifically. Some participants in 
the current study’s sample may already be engaging in these strategies and they 
should be further encouraged, in addition to attempting to normalise short sessions 
and PrEP and lubricant use. These kind of positive messages are likely to be more 
effective than adding another message telling MSM that the kind of sex they are 
having is harmful or dangerous.  
While ARVs have been shown to be effective at drastically reducing the 
transmission risks associated with HIV, CAI continues to be a source of other STI 
and BBV transmission. The next hypothesis explored some of the possible 
contributors to CAI. Based on the idea that PrEP is a new tool in the battle against 
HIV and recent research (Vernazza & Bernard, 2016) and in turn, recent public 
health campaigns (Prevention Access Campaign, 2016), have found that an 
undetectable viral load means the HIV infection is untransmitable; the focus has 
shifted slightly onto the secondary harms. These secondary harms explore the idea 
that people in the sample who were are lower risk for HIV acquisition or 
transmission (on PrEP or UVL) were putting themselves at the mercy of other risks 
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by having CAI (Kojima, Davey, & Klausner, 2016). In addition to this, the current 
study was interested in any effect that chemsex contributes to CAI. As was reported, 
all three of these variables make a significant contribution to the outcome of CAI. As 
such, the concerns around secondary harms are validated by this result.  
ARVs decrease the likelihood of acquiring or transmitting HIV and while 
these risks are different, the protective mechanisms (the use of ARVs) are similar 
enough that it may result in similar behaviours. The present study has found that both 
PrEP and having an UVL contribute to the outcome of CAI. As previously discussed, 
ARVs mean that people now fear HIV less (Van de Ven et al., 2002) and evidence 
suggests that other risks associated with high risk sex are perceived as less severe 
(Bourne et al., 2014). This would appear to be an explanation for the also increased 
rates of STIs within the chemsex sample.  
The final hypothesis explored the idea that participants using ARVs were 
more likely to be engaging in CAI and therefore likely to be acquiring more STIs. It 
was established with the testing of hypothesis 4 that people using ARVs and people 
having chemsex are having more CAI while drunk or high, the final hypothesis of 
this study showed that this is not translating directly into an increase in STIs. The 
results of the final hypothesis showed that the use of PrEP and having chemsex 
significantly contribute to the outcome of STIs but chemsex and UVL do not. 
However in hypothesis 4 the results concluded that chemsex, UVL and PrEP all 
contribute to CAI. The conclusion from these two results is that all of the effect of 
chemsex on STIs is being absorbed by the CAI variable. So chemsex has an effect on 
CAI which has an effect on STIs but chemsex does not have a direct effect on STIs. 
The implication of this result is that, chemsex, while a concern from a substance use 
perspective, is not as much of a concern from a sexual health perspective as the 
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behaviour of CAI specifically. McCormack et al. (2016) reported that in one of the 
major PrEP studies there was no increase in the number of STIs reported with the use 
of PrEP. While it is true that the people most at risk of HIV (and in turn, other STIs) 
are the ones most likely to be using PrEP, the current study would indicate that MSM 
who are using PrEP are getting STIs at an increased rate over those who are not on 
PrEP. This result should be interpreted with caution as it may be a reflection that the 
most at risk group is most likely to be using PrEP, rather than assuming that PrEP is 
causing more CAI. Interestingly, for people who were HIV positive with UVL, 
having an UVL is not a factor contributing to the acquisition of STIs. While in some 
ways these people are at a similar level of risk as people using PrEP, an HIV 
diagnosis clearly has an impact on their behaviours and therefore isn’t translating 
into an increase level of STI reports. Much of the qualitative responses cited by 
Bourne et al. (2014) indicated that HIV positive men tended to be more careless with 
condom use however the present study would indicate otherwise.    
Theoretical and Practical Implications 
The National Drug and Alcohol Strategy 2016-2025 report has highlighted 
the substantial need for intervention within the LGBTIQ population. They note that 
while best practice approaches are not well defined, strategies that engage the 
community though peer and community based programs, that are able to target 
specific LGBTIQ issues such as discrimination and bullying, are most likely to be 
successful. The report also notes that health staff who are well informed regarding 
the issues effecting the community are most likely to be effective in delivering 
effective drug and alcohol interventions (Intergovernmental Committee on Drugs, 
2015; Mullens et al., 2017). In light of this, local LGBTI organisations, including, 
but not limited to QuAC could consider some targeted drug harm reduction work, 
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particularly in relation to crystal methamphetamine. Given the current study’s results 
in regard to methamphetamine, the group most likely to benefit from such 
interventions would be people who are not currently taking ARVs, however the 
results show that anything increasing CAI (which crystal methamphetamine is 
associated with) is associated with more STIs, therefore anyone using crystal 
methamphetamine should be targeted for appropriate LGBTI intervention. In terms 
of drug use, GHB and mephedrone were found to be of little concern in the current 
study and as per the most recent GCPS, focussing on the high levels of marijuana 
and amyl nitrate use in the community at large, is likely to be the best use of 
resources.    
While not unexpected, the result that people using PrEP are more likely to be 
having CAI and more likely to have acquired an STI in significant cause for concern. 
Early research (McCormack et al., 2016) hoped that only people already at high risk 
(not using condoms anyways) would take up PrEP and be protected against HIV and 
other PrEP users would use PrEP in addition to their existing barrier methods. This 
may still be the case and the current study’s results would indicate that it likely is. 
Given that overall reports of STIs were higher in the current study (approximately 
18%) than in previous GCPS’s, which have remained stable at around 12% for the 
last four years. People with an UVL, in the current study, were more likely to have 
CAI however this did not translate into increased risk of STIs. This may be because 
the variance was accounted for by some of the other variables, such as monogamy, or 
may be that there were not enough participants in this group to detect any effect. 
Regardless, one of the important factors when working with people who are HIV 
positive is not only the STI risks associated with CAI but the possibility of HIV co-
infection or superinfection (Blackard, Cohen, & Mayer, 2002). This occurs when a 
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person acquires two differing strains of the HIV virus. This is of particular concern 
for people with a detectable viral load or people with sub-optimal ARV adherence 
(Redd et al., 2013). While it’s important for health staff to be aware of all the 
possible risks of co-infection, as well as the risks associated with drug resistance, 
from the point of view of risk reduction it’s probably not helpful for all MSM to be 
aware of all the risks. This is likely to become overwhelming and the risks may be 
interpreted as either smaller or greater than they actually are. These possible 
misinterpretations have the potential to causes more harm that encouraging a ‘use 
condoms, if and when you can’ message, particularly for this population, who are at 
higher risk than the population of MSM who engage in less extreme, less frequent 
CAI and drug use.  
In thinking about the implications of these results for clinical practice, it is 
worth noting some of the areas in which interventions may be most effective. While 
the current study did not find any demographic factors associated with chemsex 
engagement, personality factors have previously been explored as a factor likely to 
influence high risk behaviours (Ersche, Turton, Pradhan, Bullmore, & Robbins, 
2010; Zuckerman & Kuhlman, 2000). In addition, sexual activity has also been the 
subject of research on the personality trait of sensation seeking. In fact, this 
phenomenon has been studied within gay male populations looking to classify some 
of the relationships between gay male substance use and sexual activity (Dolezal, 
Meyer-Bahlburg, Remien, & Eva Petkova, 1997). While not practical to administer 
personality assessment for every one-on-one sexual health consultation, it is a factor 
that clinicians should be aware of on an individual level as well as on a group level. 
Personality traits may influence the interaction with social norms and an individual’s 
influence on the group, it may also influence how a person interprets health 
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promotion messages. When considering the personal and personality factors 
potentiality contributing to chemsex, it is worth taking a brief look at the 
psychological interventions often used to encourage safer practices. Motivational 
interviewing, which is based on the Stages of Change Model, is often used to 
increase motivation to engage in health enhancing behaviours (Shernoff, 2006; 
Stuart, 2013). Motivational interviewing involves “directive, client centred 
counselling style for eliciting behaviour change by helping clients to explore and 
resolve ambivalence” (Rubak, Sandbæk, Lauritzen, & Christensen, 2005, p. 305, 
p.305). It has been used as a technique for increasing change behaviours in clients 
since its inception in 1983. Rubak et al. (2005) report a range of effectiveness from 
46% to 80% depending on the behaviour under consideration and the patient 
population. While motivational interviewing has been used in this sector for a long 
time (Berg, Ross, & Tikkanen, 2011), it is worth considering how this kind of 
psychotherapy can be applied to chemsex behaviour specifically. While individual 
level intervention is helpful, targeting behaviour at a group level has a long history of 
succuss and is captured in a number of health behaviour models (Armitage & 
Conner, 2000; Merzel & D’Afflitti, 2003). 
However there is a distinct difference between health promotion, which tends 
to be broader, and attempting to change social or group norms. Sometimes this 
change can be facilitated by peer educators/health promotors, which is a method that 
has experienced significant success within the LGBTIQ community. A number of 
previous LGBTIQ campaigns have focused on the message of ‘keep your mates safe’ 
and targeted the idea of health behaviours for the greater good, which is applicable to 
HIV and STI transmission particularly but is also applicable to substance use in a 
chemsex context. The approach of targeting all avenues with both individual 
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intervention as well as addressing some of the normative subculture of chemsex, are 
likely to garner the best results in terms of harm minimisation. As discussed, the 
current study and its health promotion recommendations are supported and informed 
by a number of theoretical models of health behaviour. Of particular relevant in 
targeting normative social behaviour’s is social cognitive theory, which has a long 
history of theoretically supporting health promotion that targets change of group 
behavioural norms (Bandura, 2004).            
Strengths, Limitations and Future Directions 
The current study had a number of strengths, the most significant of which 
was that the project was specifically requested by a grass roots community health 
organisation who wanted to better inform their practice. As a result, they had strong 
motivation to be heavily involved in the project. This resulted in strong community 
engagement and a sizable sample of over 650 participants surveyed in a three month 
period. This means health promotion staff are invested in the results and are 
committed to developing targeted health promotion interventions based on the results 
of this study. This research also contributes to an emerging body of literature on 
chemsex in Australia and the impacts of it on a marginalised group within our 
society. This aligns with one of the aims of the National Drug Strategy 2016-2015 to 
target and collaborate with the LGBTIQ community to improve rates and negative 
consequences of substance use within the LGBTIQ community (Intergovernmental 
Committee on Drugs, 2015). In addition to contributing to the body of research on 
chemsex specifically, the current study has further identified and specified the need 
for LGBTIQ specific substance use interventions. While Australian research has 
indicated that most substance use support services in Australia have positive and 
constructive attitudes to the LGBTI community (Mullens et al., 2017), Bourne et al. 
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(2014) specified that many chemsex participants had a strong preference for 
accessing substance use support services in the context of sexual health because there 
was more knowledge and less judgement around their same-sex sexual behaviours. 
The current study is one of the first to look at chemsex in Australia with a 
quantitative methodology. To the knowledge of the author, it is the first quantitative 
chemsex study in Australia. This bolsters the results and gives them additional 
credibility from a prevalence and objectivity perspective. 
 The main limitations of this study relate to the sampled population. Data was 
primarily collected by QuAC staff and volunteers at the QuAC office and at local 
venues. While online advertising was effective, overall the sample was heavily 
biased to the inner city centre of Brisbane, which has a very high population of gay 
and other MSM. So while this study provides good representation to this group, more 
marginalised, potentially disenfranchised, rural, and other underrepresented groups, 
are not necessarily represented in this study. In addition, other major centres in 
Queensland such as Cairns and Townsville were not heavily represented in this study 
either. Future research and intervention should aim to target these populations as 
they have a tendency to be under represented in research and underserviced by 
community specific health care providers. Another limitation of note is that the 
current study did not collect any event level data. Event level data can be helpful in 
eliciting information about specific behaviours and can be more accurate than 
retrospective reporting (Steptoe, 2010). Future chemsex research using event level 
data may help understand some of the more specific aspects of chemsex behaviour. 
There are a number of additional areas that this study touched on but did not directly 
investigate. While PrEP is still in its trial phase throughout Australia, data on 
episodic use of PrEP and the relationship between PrEP use and STIs has not been 
CHEMSEX  70 
thoroughly investigated. There are still questions around PrEP’s contribution to STI 
rates and if MSM who previously would have protected themselves against both HIV 
and other STIs are now only protecting themselves against HIV. This would be a 
valuable piece of information from a health promotion perspective, particularly for 
chemsex. Episodic use of PrEP is also emerging as an area for investigation. Big 
LGBTIQ events such as Mari Gras and Big Gay Day have always been associated 
with parties involving a lot of sexual activity. Investigations around the efficacy of 
short term PrEP use for these events is likely to shed light on additional ways MSM 
might be able to protect themselves from HIV (Elsesser et al., 2016). The current 
study did not address how engagement and connection to the LGBTIQ community 
impacts on participation in chemsex. Engagement with the community has been 
shown to have positive outcomes for mental health (Ramirez-Valles, 2002) and it 
may have an influence both on the behaviour of chemsex, in addition to levels of 
engagement in harm minimisation tools.        
Summary and Conclusion 
The current study has explored chemsex in Australia using a quantitative 
design to shed much needed light on this emerging public health concern. MSM 
continue to be marginalised and represent the vast majority of new HIV infections in 
Australia. Research that helps to identify some of the determinates of these new 
infections as well as other harms associated of drug use and high risk sexual activity, 
are important in order to develop effective health promotion programs and 
interventions. The studies’ findings included: that crystal methamphetamine use 
during chemsex is associated with an increase in CAI. That increase in chemsex 
sexual session length increases the association with CAI. That chemsex, PrEP use 
and UVL all have an association with an increase in CAI, and finally that CAI and 
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PrEP use are associated with more reports of STI diagnosis. It is hoped that this 
research is able to make a positive contribution both to public health outcomes for a 
marginalised group, both in terms of implementation and possibly funding of public 
health interventions. As well as contribute to the academic body of work on MSM 
and their health outcomes.  
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